SCODiA Report by MLBI Lab

Single-Cell Atlas of Kidney Cancer: Renal Epithelial Pathobiology and Tumor Microenvironment Interactions

This report details a single-cell analysis of kidney tissue, revealing profound molecular and cellular alterations in Kidney Cancer. Malignant renal epithelial cells are characterized by aneuploidy, dysregulated cell cycle, and metabolic reprogramming. The tumor microenvironment exhibits extensive cell-cell crosstalk, notably between tumor cells and macrophages, fostering immune evasion and tumor growth. These findings identify critical pathways and surface markers with therapeutic potential.

Contents

0. Dataset overview
1. UMAP Visualization of Cell Identity and State in Kidney Tissue
2. Single-Cell UMAP Visualization of Major Cell Type Scores, Ploidy, and Annotations
3. Cell Type Subtype Marker Expression Dot Plot Analysis
4. Copy Number Variation Analysis in Renal Epithelial Cells from Kidney Tissue
5. CNV-Based UMAP Embedding Revealing Cell Type, Ploidy, Condition, and Sample Heterogeneity
6. Minor Cell Type Population Analysis in Kidney Cancer
7. Population Analysis of T Cell Subsets in Normal and Kidney Tumor Tissues
8. Macrophage Subset Population Analysis in Kidney Cancer
9. Differential Proportion of Macrophage (M2C) Subpopulation in Kidney Cancer
10. Ploidy Distribution of Renal Epithelial Cells in Kidney Tissue Across Normal and Tumor Conditions
11. Cell-Cell Interaction Patterns in Normal and Kidney Tumor Microenvironments
12. Condition-Specific Cell-Cell Interaction Patterns in Kidney Cancer
13. Condition-Specific Cell-Cell Interactions in Kidney Cancer Involving Immune and Cell Cycle Pathways
14. Renal Epithelial Cell Condition-Specific Surfaceome Markers: Potential Therapeutic Targets in Kidney Cancer
15. Macrophage Condition-Specific Surfaceome Markers in Kidney Cancer
16. Condition-Specific Surfaceome Markers in Kidney CD4+ T Cells
17. Dysregulated Cell Cycle Gene Expression in Renal Epithelial Cells from Kidney Cancer
18. Gene Ontology (GSA) Analysis of Renal Epithelial Cells in Kidney Tissue
19. Gene Set Enrichment Analysis (GSEA) Across Kidney Tissue Cell Types in Tumor and Normal Conditions
20. Discussion
21. Query List

0. Dataset overview

Dataset Summary

• This AnnData object contains single-cell RNA-seq data for 26,502 cells and 22,483 genes.
• The data is from human Kidney tissue, with samples categorized into 'tumor' and 'normal' conditions.
• Observed cell ploidy includes 17,401 Diploid cells (65.7%), 9,089 Aneuploid cells (34.3%), and 12 Unclear cells (0.0%).
• The resolved tumor-origin cell type is identified as 'Renal Epithelial cell'.
• Copy Number Variation (CNV) estimates are available.
• The reference condition for differential expression (DEG), gene set enrichment analysis (GSEA), and gene set analysis (GSA) is 'normal'.

Cell Type Annotation Levels

• Major Cell Types: unassigned, Myeloid cell, T cell, Endothelial cell, Stromal cell, Mast cell, B cell, Renal Epithelial cell.
• Minor Cell Types: unassigned, Macrophage, T cell CD4+, T cell CD8+, Endothelial cell, Smooth muscle cell, Dendritic cell, Mast cell, Plasma cell, Intercalated cell, Podocyte, Fibroblast, Collecting Duct Principal cell, Thick Ascending Limb, B cell, NK cell, ILC, Proximal Tubule, Distal Tubule.
• Subset Cell Types: a more granular list including specific macrophage subtypes, T cell subtypes, and various kidney-specific epithelial cells.

Precomputed Results

• Cell-Cell Interaction (CCI): Results from CellPhoneDB are available per condition and per sample.
• Differential Expression Genes (DEG): Results are precomputed for each major/minor cell type, comparing one condition against the rest.
• Gene Set Enrichment Analysis (GSEA): Results are precomputed for each major/minor cell type, comparing one condition against the rest.
• Gene Set Analysis (GSA_up): Gene Ontology (GO) results are precomputed for each major/minor cell type, comparing one condition against the rest.

Inferred Biological Context

• The dataset is inferred to be related to Kidney Cancer, based on the presence of tumor/normal conditions, aneuploidy, and tumor-originating Renal Epithelial cells in Kidney tissue.
• This inference is computational and does not constitute a clinical diagnosis; specific cancer subtype or stage cannot be determined.

Available Cell Types for DEG, GSEA, GSA/GO Analyses

• For DEG, GSEA, and GSA/GO analyses, results are available for the following cell types: Endothelial cell, Macrophage, Renal Epithelial cell, Smooth muscle cell, T cell CD4+, T cell CD8+.

1. UMAP Visualization of Cell Identity and State in Kidney Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a series of Uniform Manifold Approximation and Projection (UMAP) plots, visualizing the global transcriptional landscape of 26,502 single cells from kidney tissue. The UMAPs are colored by various cellular and sample annotations: condition (tumor/normal), sample, celltype_major, celltype_minor, ploidy_dec (aneuploid/diploid/unclear), and celltype_subset. These visualizations provide an essential overview of cell heterogeneity, the relationship between different cell populations, and how these populations relate to disease state, sample origin, and ploidy status within the embedding space.

Visual Summary

Condition

The UMAP colored by condition (tumor vs. normal) reveals a clear separation between cells originating from normal and tumor tissues. While a large central cluster is predominantly composed of normal cells (purple), distinct and somewhat interconnected clusters appear to be enriched with tumor cells (red). There is also a region where normal and tumor cells appear to mix, suggesting shared cell types or transitional states, or immune infiltration into the tumor microenvironment.

Sample

The sample UMAP shows that cells from different samples are generally well-interspersed across the majority of the embedding space, indicating a largely successful integration of data and minimal strong batch effects driving major cluster formation. However, some specific samples (e.g., SI_18854, SI_18855, SI_19703) tend to dominate particular regions of the 'normal' clusters, while others (e.g., SI_23843, SI_23459, SI_22605) are more prominent in 'tumor'-associated clusters. This suggests that certain samples contribute more cells to specific biological states or conditions.

Celltype_major

The celltype_major UMAP demonstrates clear clustering of broad cell types. 'Renal Epithelial cell' (light green) forms a large, prominent cluster, and appears to largely overlap with the 'tumor'-enriched regions identified in the condition UMAP. 'Myeloid cell' (orange) and 'T cell' (light blue) populations also form distinct clusters, some of which are intermingled with the 'Renal Epithelial cell' cluster in tumor regions, indicating immune cell presence in the tumor microenvironment. 'Endothelial cell' (red) and 'Stromal cell' (dark green) also form distinct populations.

Celltype_minor

The celltype_minor UMAP provides a more granular view of cell types. Within the 'Renal Epithelial cell' major cluster, minor types like 'Proximal Tubule' (light green), 'Collecting Duct Principal cell' (dark red), 'Thick Ascending Limb' (dark blue), and 'Distal Tubule' (red) are identifiable. The immune cell clusters further resolve into 'Macrophage' (light yellow), 'T cell CD4+' (blue), and 'T cell CD8+' (dark blue). Importantly, many of the epithelial cell types specific to normal kidney physiology ('Proximal Tubule', 'Distal Tubule', 'Collecting Duct Principal cell', 'Podocyte', 'Intercalated cell') occupy regions that overlap with the 'normal' condition, while the less differentiated 'Renal Epithelial cell' (from celltype_major) seems to be the one predominantly linked to tumor.

Ploidy_dec

The ploidy_dec UMAP is highly informative. 'Aneuploid' cells (red) predominantly occupy the same distinct clusters that were enriched for 'tumor' cells in the condition UMAP and 'Renal Epithelial cells' in the celltype_major UMAP. 'Diploid' cells (light yellow) are widely distributed, making up the bulk of the 'normal' clusters and also co-existing in some regions with aneuploid cells, potentially representing normal stromal or immune cells within the tumor microenvironment. This strong co-localization of aneuploidy with specific clusters of renal epithelial cells in tumor samples provides robust evidence for the malignant origin of these cells.

Celltype_subset

The celltype_subset UMAP provides the highest resolution of cell types, detailing specific subtypes like 'Macrophage (M1)', 'Macrophage (M2B)', 'T cell (Cytotoxic)', 'T cell (Naive)', 'Proximal Convoluted Tubule S1_S2', 'Distal Convoluted Tubule', etc. This granular view allows for a more detailed understanding of the specific cellular components within each cluster and how they might differ between conditions. For example, specific macrophage or T cell subsets might be differentially enriched in tumor-associated regions compared to normal tissue.

Biological Interpretation

The UMAP visualizations provide compelling evidence for significant biological differences between kidney tumor and normal tissue at a single-cell resolution.

1. Tumor-specific Cell Populations: A major finding is the clear spatial separation of cells from tumor and normal conditions. The clusters predominantly composed of 'tumor' cells are highly enriched for 'Aneuploid' cells and specifically for Renal Epithelial cell types, which is consistent with the inferred diagnosis of Kidney Cancer, where malignant transformation often originates from renal epithelial cells and involves chromosomal instability (aneuploidy) [PubMed Search: "kidney cancer aneuploidy renal epithelial cell origin"].
2. Immune Microenvironment: The presence of 'Myeloid cell' and 'T cell' populations intermingled with the 'Renal Epithelial cell' clusters in the tumor-associated regions suggests an active immune infiltration into the tumor microenvironment. Further investigation into the celltype_subset data for these immune cells (e.g., Macrophage (M1/M2), T cell (Cytotoxic), T cell (Treg)) could reveal the specific immune landscape of the tumor.
3. Distinct Normal Kidney Epithelium: The 'normal' condition regions of the UMAP are characterized by diverse diploid 'Renal Epithelial cell' subtypes (e.g., Proximal Tubule, Distal Tubule, Collecting Duct Principal cell), reflecting the complex cellular architecture of a healthy kidney. These populations are largely distinct from the aneuploid, tumor-associated renal epithelial cells.
4. Integrated Cell Identity and Genomic State: The strong concordance between the 'tumor' condition, 'Aneuploid' status, and Renal Epithelial cell identity (particularly in the less differentiated or transformed epithelial populations) provides a powerful validation of the cell type annotations and the biological relevance of the detected aneuploidy. This indicates that the UMAP effectively captures the molecular changes associated with oncogenic transformation.

Annotation Notes

The provided UMAPs demonstrate robust clustering and clear separation of cells based on major biological distinctions like condition, ploidy, and cell type.

• Annotation Quality: The distinct clustering of various celltype_major, celltype_minor, and celltype_subset populations suggests high quality and specificity in cell type annotation.
• Embedding Structure: The embedding effectively separates distinct biological states, particularly between tumor and normal, and highlights the relationship between cellular identity, genomic stability (ploidy), and disease condition.
• Sample Distribution: While samples are generally well-mixed, some regional enrichment of specific samples is observed. This should be considered in downstream analyses to ensure that any observed differences are biological and not driven by sample-specific technical variation or unequal representation of specific cell states across samples. However, the overall good mixing across most clusters indicates that the major biological signals are robust.

2. Single-Cell UMAP Visualization of Major Cell Type Scores, Ploidy, and Annotations

[Analysis Visualization Results]...

Analysis Overview

This analysis provides a comprehensive visualization of the single-cell RNA-seq dataset on a UMAP embedding. It displays the distribution of scores for each major cell type (HiCAT_major_score), the inferred ploidy status (ploidy_dec), and the final major cell type annotations (celltype_major). This visualization serves to confirm the quality of cell type assignments and to visually identify cell populations based on their defining characteristics and genomic stability.

Visual Summary

The UMAP plots provide a detailed view of cell populations:

• Major Cell Type Scores (HiCAT_major_score): Eight plots show the distribution of confidence scores for each major cell type. Regions with high scores (yellow/green) indicate a strong presence of that specific cell type.
  • T cells show two main clusters of high scores, primarily in the lower-right and a smaller distinct group in the upper-left.
  • B cells are localized to a more compact cluster with high scores in the upper-right, distinct from T cells.
  • Myeloid cells exhibit high scores concentrated in a large, well-defined cluster on the far right side of the UMAP.
  • Mast cells show a more diffuse pattern, with a small region of higher scores.
  • Endothelial cells form a clear, high-scoring cluster in the top-middle and upper-left regions.
  • Stromal cells define a distinct cluster with high scores predominantly in the lower-middle part of the UMAP.
  • Renal Epithelial cells display high scores across several significant clusters, most prominently in the upper-right and some central areas, suggesting multiple subpopulations or states.
• Ploidy Status (ploidy_dec): This plot distinguishes cells by their inferred ploidy.
  • Aneuploid cells (maroon) are prominently clustered in the upper-right region and some central areas, overlapping significantly with several clusters.
  • Diploid cells (cream) constitute the majority of the remaining clusters, including immune and stromal cell populations.
  • Unclear cells are very few and sparsely distributed.
• Major Cell Type Annotations (celltype_major): This plot shows the final assigned major cell type for each cell, using a distinct color per type.
  • The overall UMAP structure reveals well-separated clusters for each major cell type, consistent with their respective score distributions. For instance, the light green Renal Epithelial cell clusters align well with the regions of high HiCAT_major_score: Renal Epithelial cell.
  • Immune cells (T cell, B cell, Myeloid cell) and stromal/endothelial cells are clearly delineated into distinct populations.

Biological Interpretation

• Consistency of Cell Type Annotation: The strong congruence between the HiCAT_major_score plots and the celltype_major annotation plot provides high confidence in the cell type assignments. Each cell type score accurately highlights the regions of the UMAP where that particular cell type is ultimately annotated, indicating robust and consistent cell identity mapping.
• Identification of Malignant Renal Epithelial Cells: A critical observation is the significant overlap between the Renal Epithelial cell clusters (light green) and the Aneuploid cell population (maroon), particularly in the large cluster in the upper-right of the UMAP. This finding strongly supports the inferred context of Kidney Cancer and the resolution of Renal Epithelial cell as the tumor-origin cell type. Aneuploidy, a hallmark of cancer, is directly co-localized with the cells identified as originating from the kidney epithelium, validating their likely malignant nature.
• Tumor Microenvironment Composition: The clear delineation of other cell types, such as T cells, Myeloid cells, Endothelial cells, and Stromal cells, which are predominantly Diploid, suggests the presence of both immune and stromal components within the tumor microenvironment and normal kidney tissue. These non-malignant cells play crucial roles in tumor progression, immune response, and tissue maintenance.
• Dataset Integrity: The well-separated and distinct clustering of different major cell types on the UMAP, along with the consistent scoring and annotation, indicates a high quality single-cell dataset with effective dimensionality reduction and clustering.

Annotation Notes

• This analysis confirms the accuracy and reliability of the major cell type annotations. The high correlation between the specific cell type scores and the final assigned labels validates the annotation pipeline.
• The spatial relationship between Aneuploid cells and Renal Epithelial cells provides strong evidence for the identification of the tumor cell population within the dataset.
• The clear separation of diverse cell types on the UMAP underscores the distinct transcriptional profiles present in the kidney tissue, allowing for targeted downstream analyses of specific cell populations.

3. Cell Type Subtype Marker Expression Dot Plot Analysis

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot illustrating the expression levels of marker genes across various celltype_subset groups in single-cell RNA-seq data from human Kidney tissue. The plot serves as a crucial visualization for verifying the distinct identities of computationally derived cell clusters against known biological markers. Each row represents a celltype_subset, and each column represents a marker gene. The size of the dot corresponds to the fraction of cells within a group expressing the gene, while the color intensity reflects the mean expression level of the gene in that group. The bar chart on the right indicates the total number of cells belonging to each celltype_subset.

Visual Summary

The dot plot clearly delineates distinct expression patterns for most celltype_subset groups, forming characteristic blocks of highly expressed, specific markers.

• Strong Specificity: Many cell types exhibit a high fraction of expressing cells (large dots) and high mean expression (dark red color) for a unique set of markers, suggesting well-defined and robust annotations. Examples include distinct clusters of immune cells (e.g., Macrophages, T cells), stromal cells (e.g., Smooth muscle cell, Fibroblast), and specific renal epithelial cells (e.g., Collecting Duct Principal cell, Intercalated cell, Thick Ascending Limb).
• Expression Distribution: The legend indicates that the mean expression ranges from low (light red) to high (dark red), and the fraction of cells expressing ranges from 20% to 80%+. The varying dot sizes and color intensities provide a quick visual assessment of both prevalence and abundance of gene expression within each cell group.
• Cell Group Sizes: The bar chart on the right displays the total cell count per celltype_subset, showing a wide range in population sizes, from smaller groups like DC (Inflammatory) (35 cells) to larger populations such as Fibroblast (3513 cells) and Proximal Convoluted Tubule S1_S2 (2296 cells).
• Overlapping Markers: While many markers are specific, some genes show expression across multiple related cell types, particularly within the Macrophage subtypes or certain kidney tubule segments, which is expected for closely related cell populations.

Biological Interpretation

The expression profiles of marker genes largely support the biological identities assigned to the celltype_subset populations, with insights into their specialized functions.

Immune Cell Subtypes:

• Macrophages (M1, M2A, M2B, M2C, M2D): These subtypes show a common core macrophage marker, CD68 [GeneCards], and also exhibit subtype-specific markers. For example, CLEC7A (Dectin-1) is notably expressed in Macrophage (M1), consistent with its role in pro-inflammatory responses. SOCS3 is observed in Macrophage (M2A), and SRGN (Serglycin) in Macrophage (M2B), indicating distinct functional polarization states, which are relevant in the context of kidney cancer given the role of tumor-associated macrophages.
• Dendritic Cells (Classical, Inflammatory): Markers like CD1C, CLEC9A, CD83, and CD86 are evident in DC (Classical), aligning with their antigen-presenting function [PubMed Search]. DC (Inflammatory) shows markers like THBD and CD1A.
• T cells (Cytotoxic, Th1, Th17, Th22, Treg): These T cell subsets are well-defined by their established markers. CD8A and GZMK clearly mark Cytotoxic T cells [GeneCards], crucial for anti-tumor immunity. STAT4 for Th1, RORA for Th17, and BATF for Th22 reflect their unique transcriptional programs and cytokine profiles. TNFRSF18 (GITR) and LGALS1 (Galectin-1) are observed in T cell (Treg), indicating their immunosuppressive roles.
• Plasma cells: Identified by XBP1, MZB1, and JCHAIN, which are characteristic of activated B cells differentiating into antibody-secreting plasma cells.
• Mast cells: Marked by KIT (CD117) and TPSAB1 (Tryptase alpha/beta 1) [GeneCards], canonical markers for mast cell lineage and function.

Stromal and Endothelial Cells:

• Fibroblasts: Strongly express DCN (Decorin), COL1A1, COL1A2, COL3A1 (collagen genes), and LUM (Lumican), reflecting their extracellular matrix remodeling and structural support roles [GeneCards].
• Smooth muscle cells: Characterized by ACTA2 (alpha-smooth muscle actin) [GeneCards], MYL9, TPM2, and TAGLN, consistent with contractile functions.
• Endothelial cells (General and Tip): Express classic endothelial markers such as ESM1, ANGPT2, DLL4, C1R, and COL6A2. ANGPT2 and DLL4 are particularly enriched in Endothelial tip cells, consistent with their role in angiogenesis [PubMed Search].

Renal Epithelial Cells:

• Collecting Duct Principal cell: Exhibits expression of HSD11B2, CLU, KLK1, and RHCG. RHCG (Rhesus C Glycoprotein) is a known marker of collecting duct cells involved in ammonia transport [GeneCards].
• Intercalated cell: Strongly expresses ATP6V0D2 and ATP6V1G3, subunits of vacuolar H+-ATPase, consistent with their role in acid-base regulation in the kidney tubules.
• Thick Ascending Limb: Distinctly marked by UMOD (Uromodulin) [GeneCards] and SLC12A1 (NKCC2) [GeneCards], both highly specific and well-established markers for this segment of the nephron.

Annotation Notes

Based on the marker expression patterns, most celltype_subset annotations are well-supported by canonical gene markers, confirming the quality of the cell type assignments. However, some areas warrant further attention or refinement:

• Podocyte Annotation: The markers provided for "Podocyte" (NAPSA, SLCO4C1, SLC39A8, CNDP2, SLC5A3) do not include highly specific and canonical podocyte markers such as *NPHS1* (Nephrin), *PODXL* (Podocalyxin), or *WT1*. While some of the listed genes may be expressed in podocytes, their specificity appears lower compared to other cell types. For instance, NAPSA is more commonly associated with proximal tubules. This suggests that the current marker set might not fully capture the unique identity of podocytes, or that this cluster may represent a broader or less mature renal epithelial population.
• Proximal Tubule Segment Overlap: The Proximal Convoluted Tubule S1_S2, Proximal Convoluted Tubule S3, and Proximal Straight Tubule S3 annotations show considerable overlap in their marker expression. Critically, these clusters, along with Podocytes, all express SLC5A3. More concerningly, SLC12A1, a definitive marker for the Thick Ascending Limb (TAL) cells, is also highly expressed across these proximal tubule segments (S1_S2, S3, Proximal Straight Tubule S3). Additionally, SCNN1A, a known collecting duct marker, is found in Proximal Convoluted Tubule S3 and Proximal Straight Tubule S3, and also somewhat in Thick Ascending Limb. This observed co-expression of markers typically associated with different nephron segments suggests potential challenges in precisely delineating these very fine-grained kidney epithelial subtypes using the current marker set or might indicate transitional states or misassignments.
• Refinement Opportunities: For the aforementioned kidney epithelial cell types, incorporating additional, highly specific markers or re-evaluating the clustering based on a more comprehensive set of renal epithelial markers could enhance the resolution and confidence in their annotations.

4. Copy Number Variation Analysis in Renal Epithelial Cells from Kidney Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates copy number variations (CNVs) within the Renal Epithelial cell population, identified as the tumor-origin cell type in this kidney dataset. The primary goal is to visualize and summarize significant genomic amplifications and deletions across different samples, providing insights into the genomic instability characteristic of cancer. The results are presented as a heatmap of log2(CNR) values across genomic spots for individual samples and a summary plot highlighting frequently amplified cytogenetic bands and their associated genes.

Visual Summary

CNV Heatmap for Renal Epithelial Cells

The heatmap displays the log2(CNR) (Copy Number Ratio) values across the genome (genomic spots, ordered by chromosome) for Renal Epithelial cells, grouped by sample. Red indicates genomic amplifications (gain of copy number), while blue indicates deletions (loss of copy number).

• Inter-sample Heterogeneity: Significant variability in CNV patterns is observed across different samples. Some samples (e.g., SI_19703, SI_21561, SI_22604) exhibit widespread and strong amplifications (dark red) and deletions (dark blue) across multiple chromosomes, indicative of substantial genomic instability. In contrast, other samples (e.g., SI_18856, SI_21255, SI_22369) show fewer or less pronounced CNV events.
• Recurrent Amplifications: Several genomic regions show recurrent amplifications across multiple samples, particularly within samples SI_19703, SI_21561, and SI_22604. These include distinct bands on chromosomes 1, 3, 5, 12, and 14, which are highlighted and labeled on the heatmap.
• Segmental vs. Whole-Chromosome Changes: The CNVs appear as segmental changes rather than whole-chromosome aneuploidies in many cases, though some large regions of gain/loss are visible. This fine-grained resolution allows for the identification of specific affected cytogenetic bands.

Summary of Significantly Amplified Regions

The accompanying summary plots provide a quantitative overview of the significantly amplified regions:

• Average log2(CNR) per Cytogenetic Band (Left Panel): This heatmap focuses on samples (SI_19703, SI_21561, SI_22604) that exhibit significant amplifications and quantifies the average log2(CNR) within selected cytogenetic bands. High values (dark blue) indicate strong amplification events. For instance, SI_19703 shows strong amplifications in 3q24:3q28 (1.2) and 12q13.12:12q14.1 (1.2). SI_21561 and SI_22604 both show strong amplifications in 1q21.1:2p24.3 and 3q24:3q28, among others.
• Frequency of Amplification (Right Panel): This bar chart shows the frequency with which each identified cytogenetic band is significantly amplified across the analyzed samples.
  • Regions such as 1q21.1:2p24.3 (NFASC), 3q24:3q28 (SOX2, ECT2), 5q22.2:5q31.3, and 12q13.12:12q14.1 exhibit a high frequency of amplification (0.67), indicating they are amplified in a substantial proportion of the samples with significant events.
  • Other regions like 7q22.3:7q33, 11p15.4:11p15.2, 11q13.2:11q13.1, 14q13.2:14q24.3 (ACOT1), 15q24.1:15q25.2, and 16p13.3:16p13.3 show a lower frequency of 0.33.

Biological Interpretation

The observed extensive and recurrent CNVs in Renal Epithelial cells strongly support their identification as the tumor-origin cell type and indicate the presence of kidney cancer in these samples. The detected amplifications often involve regions known to harbor oncogenes, suggesting potential drivers of tumorigenesis and progression.

• Genomic Instability in Tumor Cells: The widespread CNVs, particularly in samples SI_19703, SI_21561, and SI_22604, are a hallmark of cancer cells. The high percentage of aneuploid cells (34.3% in the total dataset) is consistent with this observation, where renal epithelial cells from tumor samples would largely contribute to this aneuploid population.

Key Amplified Regions and Genes:

• 1q21.1:2p24.3 (NFASC): Amplification of 1q is a common event in various cancers. NFASC (Neurofascin) is an adhesion molecule whose altered expression can impact cell-cell interactions and motility, potentially promoting cancer cell invasion.
• 3q24:3q28 (SOX2, ECT2): This region is a significant hotspot for amplification.
  • SOX2 (SRY-Box Transcription Factor 2) is a well-known oncogene and a key transcription factor involved in maintaining pluripotency and self-renewal. Its amplification and overexpression are frequently observed in various cancers, contributing to tumor initiation and progression through enhanced stemness and proliferation [PubMed Search: SOX2 cancer amplification].
  • ECT2 (Epithelial Cell Transforming Sequence 2) is a Rho guanine nucleotide exchange factor (GEF) that activates Rho GTPases, crucial for cytokinesis, cell migration, and invasion. Amplification and overexpression of ECT2 are implicated in promoting proliferation, invasion, and metastasis in a wide range of human cancers, including epithelial cancers [GeneCards: ECT2]. Given that Renal Epithelial cells are the tumor origin, ECT2 amplification is particularly relevant.
• 12q13.12:12q14.1: This region is frequently amplified in human cancers and often contains oncogenes such as MDM2 and CDK4. MDM2 is an E3 ubiquitin ligase that negatively regulates the tumor suppressor p53, while CDK4 is a cell cycle kinase that promotes G1-S phase transition. Amplification of these genes can lead to uncontrolled cell proliferation and impaired cell cycle checkpoints, critical for cancer development [PubMed Search: MDM2 CDK4 amplification cancer].
• 14q13.2:14q24.3 (ACOT1): ACOT1 (Acyl-CoA Thioesterase 1) is involved in lipid metabolism. While less commonly cited as a direct oncogene, altered lipid metabolism is a known feature of cancer cells. Its amplification could contribute to metabolic reprogramming in tumor cells.

• Tumor Heterogeneity: The differences in CNV profiles across samples highlight the genomic heterogeneity of kidney cancer, even within the same inferred cell type of origin. This implies distinct molecular landscapes across different patients.

Clinical or Translational Implications

The recurrent CNV patterns observed in Renal Epithelial cells have several potential clinical and translational implications for kidney cancer:

• Biomarker Potential: The identified regions of frequent amplification (e.g., 1q21.1:2p24.3, 3q24:3q28, 12q13.12:12q14.1) could serve as biomarkers for the diagnosis, prognosis, or monitoring of kidney cancer. Detecting these specific CNVs could help confirm malignancy or predict disease aggressiveness.
• Therapeutic Targets: Oncogenes like SOX2, ECT2, MDM2, and CDK4, located within the highly amplified regions, represent promising therapeutic targets. Developing inhibitors against these genes or their downstream pathways could lead to novel targeted therapies for kidney cancer patients whose tumors harbor these amplifications.
• Understanding Disease Pathogenesis: The CNV landscape provides crucial insights into the genomic aberrations driving kidney cancer. Understanding these recurrent events can enhance our knowledge of kidney cancer biology and identify key pathways dysregulated in the disease.
• Personalized Medicine: Characterizing the CNV profile of an individual patient's tumor could help guide personalized treatment strategies, matching specific therapies to the unique molecular characteristics of their cancer.
• Prognostic Indicators: The extent and specific patterns of CNVs could correlate with patient outcomes, helping to stratify patients into different risk groups and guide treatment intensity.

5. CNV-Based UMAP Embedding Revealing Cell Type, Ploidy, Condition, and Sample Heterogeneity

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a series of UMAP plots generated using copy number variation (CNV) patterns (cnv=True in embed_cfg) as the basis for dimensionality reduction. These plots visualize the relationships between cells based on their CNV profiles, colored by various metadata annotations: celltype_major, celltype_minor, ploidy_dec, condition, and sample. The goal is to understand how cellular identity, ploidy status, disease state, and sample origin are reflected in the CNV landscape of the kidney tissue, particularly in the context of inferred Kidney Cancer.

Visual Summary

Cell Type Distribution

• celltype_major UMAP: The UMAP shows a clear separation of major cell types based on their CNV profiles. "Renal Epithelial cell" (light yellow) forms a prominent, somewhat elongated cluster that appears distinct from most other major cell types. "T cell" (light blue) and "Myeloid cell" (yellow) also form relatively distinct clusters, as do "Endothelial cell" (red) and "Stromal cell" (teal). There is some degree of mixing between certain cell types, but overall, distinct CNV patterns differentiate the major cell populations.
• celltype_minor UMAP: This plot provides a more granular view. Key kidney-specific epithelial cells such as "Proximal Tubule" (light green), "Distal Tubule" (dark blue), "Collecting Duct Principal cell" (represented by some of the "unassigned" cells in the legend due to color overlap), and "Podocyte" (light yellow) are visible within the broader "Renal Epithelial cell" major cluster. Immune cells (e.g., "T cell CD4+", "T cell CD8+", "Macrophage") occupy distinct regions, generally consistent with their major cell type counterparts, indicating that their CNV profiles also show heterogeneity at the minor cell type level.

Ploidy and Condition Association

• ploidy_dec UMAP: This plot reveals a striking pattern where "Aneuploid" cells (dark red) largely segregate into specific, relatively distinct clusters, particularly a large cluster on the right-hand side and several smaller, separate clusters. "Diploid" cells (light yellow) predominantly occupy a central and leftward region, though there is some intermingling at the boundaries, suggesting a continuum or shared CNV features in certain regions. The "Unclear" cells (dark blue) are very few and scattered.
• condition UMAP: A significant separation is observed between "normal" (dark red) and "tumor" (dark blue) cells. The "tumor" cells largely overlap with the regions identified as "Aneuploid" in the ploidy_dec UMAP, forming a dominant cluster on the right. Conversely, "normal" cells primarily coincide with the "Diploid" regions, occupying the central and left parts of the UMAP. This indicates that cells from the tumor condition frequently exhibit distinct CNV profiles compared to cells from the normal condition, and these profiles are often associated with aneuploidy.

Sample-Specific Patterns

• sample UMAP: The distribution of cells colored by individual samples (SI_18854, SI_18855, etc.) shows that while there's a general structure shared across samples, some samples contribute more heavily to specific regions or clusters. For instance, certain samples (e.g., SI_21256, SI_22605, SI_23843) appear more dominant in the regions enriched for aneuploid/tumor cells, while others (e.g., SI_18855, SI_19703) contribute significantly to the diploid/normal regions. There are also instances where a single sample might span across different CNV clusters, suggesting intra-sample heterogeneity.

Biological Interpretation

The CNV-based UMAP embedding provides critical insights into the cellular landscape of kidney tissue in the context of cancer.

1. Tumor Cell Identification and Heterogeneity: The strong co-localization of "Aneuploid" cells with cells from the "tumor" condition, predominantly within the "Renal Epithelial cell" cluster, strongly supports the inference that Renal Epithelial cells are the origin of the tumor. This finding aligns perfectly with the metadata "Resolved tumor-origin cell type: Renal Epithelial cell" and the inferred disease "Kidney Cancer." The distinct clusters formed by aneuploid/tumor cells suggest the presence of different subclones or states within the tumor, each characterized by a unique CNV profile.
2. CNV as a Determinant of Cell Identity and State: The separation of various major and minor cell types by CNV patterns indicates that even non-malignant cells can exhibit distinct CNV profiles, possibly reflecting normal physiological variations or responses to the tumor microenvironment. However, the most pronounced and distinct clusters are those associated with aneuploidy and the tumor condition, highlighting the profound impact of large-scale genomic alterations on the cellular transcriptomic state, which then manifests in distinct CNV profiles.
3. Immune Cell Infiltration and Stromal Components: Immune cells (T cells, Myeloid cells) and Stromal cells form their own distinct clusters, largely separate from the main tumor clusters. This indicates that these non-malignant cells retain relatively normal, diploid CNV profiles even within the tumor microenvironment. Their presence in the UMAP confirms the complexity of the tumor ecosystem, comprising both malignant cells and various host immune and stromal components.
4. Sample-Specific Effects: The sample UMAP highlights that while the overall CNV structure is biologically driven, there can be sample-specific patterns. Some samples contribute more heavily to the tumor-associated aneuploid clusters, reflecting the variable tumor burden or specific CNV characteristics of individual patient tumors.

Annotation Notes

• The consistency between ploidy_dec, condition, and celltype_major (specifically "Renal Epithelial cell") in the CNV-based UMAP provides strong validation for these annotations and the inferred tumor origin.
• The clear separation of aneuploid/tumor cells from diploid/normal cells on a CNV-derived embedding confirms that CNVs are a major driving force behind the observed cellular heterogeneity in this dataset.
• The presence of distinct clusters within the aneuploid/tumor population suggests potential intra-tumor heterogeneity in terms of CNV burden and specific genomic alterations, which could warrant further investigation.
• The 'unassigned' category for celltype_major and celltype_minor mostly occupies regions overlapping with the major cell types, suggesting these are likely cells that could not be confidently assigned to a specific subtype but have CNV profiles consistent with other broadly defined cell types.

6. Minor Cell Type Population Analysis in Kidney Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a stacked bar plot visualizing the relative proportions of minor cell types across individual samples, distinguishing between 'normal' kidney tissue and 'tumor' kidney tissue. Each bar represents a sample, and the colored segments within each bar indicate the percentage of different minor cell types, allowing for a direct comparison of cellular composition between healthy and cancerous environments.

Visual Summary

The population bar plot effectively illustrates distinct cellular compositional differences between normal and tumor kidney samples.

• Normal Samples (Left Panel): These samples exhibit a relatively consistent cellular landscape, predominantly composed of differentiated renal epithelial cells such as Proximal Tubule, Distal Tubule, Thick Ascending Limb, Collecting Duct Principal cell, and Podocytes. Other cell types, including Endothelial cells, Fibroblasts, and a minor presence of immune cells (e.g., Macrophages, T cells), constitute smaller proportions.
• Tumor Samples (Right Panel): A striking shift in cell type composition is observed in tumor samples.
  • Reduced Normal Epithelium: There is a notable decrease in the relative abundance of most differentiated renal epithelial cell types (Proximal Tubule, Distal Tubule, etc.) compared to normal tissue. This suggests a loss of normal kidney parenchymal structure within the tumor.
  • Increased "unassigned" Population: A substantial and highly variable proportion of cells in tumor samples are classified as "unassigned" (dark blue segment at the top of the bars). This category frequently dominates the cellular composition in tumor samples, often replacing the lost normal epithelial cells.
  • Immune Cell Infiltration: Macrophages (light yellow) show a prominent presence and increased proportion in several tumor samples (e.g., SI_22604, SI_18854, SI_22368), indicating significant immune infiltration into the tumor microenvironment. T cells (CD4+ and CD8+) are also consistently observed in both conditions but may show altered proportions in tumors.
  • Heterogeneity: The cellular composition among individual tumor samples appears more heterogeneous than among normal samples, reflecting the diverse nature of tumors.

Biological Interpretation

The observed shifts in minor cell type populations provide critical insights into the biological changes associated with Kidney Cancer.

• Loss of Differentiated Renal Epithelium and Emergence of "unassigned" Cells: The most significant finding is the marked reduction of normal differentiated renal epithelial cells (e.g., Proximal Tubule, Distal Tubule) in tumor samples, concurrently with a substantial increase in "unassigned" cells. Given that the 'Resolved tumor-origin cell type' is 'Renal Epithelial cell' and a significant fraction of cells are aneuploid in the dataset, it is highly probable that these "unassigned" cells represent the malignant renal epithelial cells. These tumor cells may have undergone dedifferentiation or adopted novel gene expression profiles that do not align with any pre-defined normal minor cell type annotations. This phenotypic plasticity is a hallmark of many cancers, where malignant cells lose their tissue-specific markers and acquire a more stem-like or mesenchymal-like state.
• Tumor Microenvironment Remodeling and Immune Infiltration: The increased proportion of Macrophages in tumor samples signifies an active immune response within the tumor microenvironment. Macrophages are key players in cancer progression, capable of promoting tumor growth, angiogenesis, and metastasis (tumor-associated macrophages, TAMs). The presence of T cells also indicates immune surveillance or an attempt at immune attack, although their specific functional states would require further investigation (e.g., through DEG or GSEA). The balance and phenotype of these immune cells are crucial for understanding the overall immune context of the tumor.
• Stromal Changes: While less dramatic, potential shifts in stromal components like Fibroblasts and Endothelial cells could reflect processes such as desmoplasia (fibroblast activation) and angiogenesis (new blood vessel formation), which are critical for tumor support and growth.

Clinical or Translational Implications

The changes in cell type populations have several potential clinical implications for Kidney Cancer:

• Diagnostic/Prognostic Markers: The shift from a highly differentiated normal epithelial cell profile to one dominated by "unassigned" cells and immune infiltrates could serve as a diagnostic signature for kidney cancer. The specific proportion of "unassigned" cells or certain immune cell subsets (e.g., specific macrophage phenotypes) might correlate with tumor stage, aggressiveness, or patient prognosis.
• Therapeutic Targets: The significant presence of Macrophages in the tumor microenvironment suggests that targeting these immune cells (e.g., by inhibiting TAM recruitment or reprogramming their pro-tumorigenic functions) could be a viable therapeutic strategy. Immunotherapies, such as checkpoint inhibitors, are also relevant given the observed immune cell infiltration.
• Understanding Tumor Heterogeneity: The variability in cell type composition among tumor samples underscores the heterogeneity of kidney cancer, which can impact treatment response and necessitates personalized therapeutic approaches.

7. Population Analysis of T Cell Subsets in Normal and Kidney Tumor Tissues

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative abundance of various T cell subsets (classified at the celltype_subset level) across individual samples, stratified by 'normal' and 'tumor' conditions. The primary goal is to identify differences in the immune cell composition, specifically within the T cell compartment, between healthy kidney tissue and kidney cancer. Given the inferred context of Kidney Cancer, understanding the T cell landscape in the tumor microenvironment is critical for characterizing immune responses and potential immune evasion mechanisms.

Visual Summary

The stacked bar plots display the percentage distribution of T cell subsets for five normal kidney samples and eight kidney tumor samples.

• Dominant Subsets: In both normal and tumor samples, the T cell (Cytotoxic) and T cell (Naive) populations constitute a substantial proportion of the T cell compartment.
• Normal Tissue Composition: Normal samples generally show a significant presence of T cell (Naive) populations, which can exceed T cell (Cytotoxic) in some samples (e.g., SI_18856, SI_21256). Other T helper subsets (Th1, Th2, Th9, Th17, Th22, Tfh), T cell (Treg), NK cell, and various ILC populations (ILC1, ILC2, ILC3 (NCR-), ILCreg, LTI) are present but in smaller proportions.

Tumor Tissue Composition

• T cell (Cytotoxic) populations remain prominent in tumor samples, often comparable to or slightly increased relative to T cell (Naive) compared to some normal samples.
• T cell (Naive) proportions appear to be generally lower in several tumor samples (e.g., SI_22368, SI_23843, SI_21561) compared to the higher levels observed in some normal samples.
• T cell (Treg) cells (dark blue segments) show a consistent presence across tumor samples, and in some tumor samples (e.g., SI_22604, SI_23459), their relative proportion might be slightly elevated compared to certain normal samples.
• NK cell and ILC subsets are detected in both conditions but remain minor components in most samples.

• Inter-sample Variability: There is noticeable variability in T cell subset composition between individual samples within both the normal and tumor groups, highlighting the heterogeneity of immune responses.

Biological Interpretation

The observed shifts in T cell subset populations provide insights into the immune landscape of kidney cancer.

1. Cytotoxic T Cells (CTLs): The sustained presence of T cell (Cytotoxic) cells in both normal and tumor tissues is expected, as these cells are critical for anti-tumor immunity. Their role in directly killing cancer cells is a cornerstone of the adaptive immune response against tumors.
2. Naive T Cells: A potential decrease in T cell (Naive) populations within the tumor microenvironment (TME) could indicate T cell activation and differentiation into effector or memory cells, or it might suggest impaired trafficking of naive T cells into the tumor. Alternatively, it could reflect T cell exhaustion or exclusion from the TME.
3. Regulatory T Cells (Tregs): The consistent presence and potential subtle enrichment of T cell (Treg) populations in some tumor samples is a critical observation. Tregs are known suppressors of immune responses, and their infiltration into the TME is a common mechanism by which tumors evade immune surveillance, contributing to a state of immune tolerance. PubMed search: regulatory T cells kidney cancer
4. T Helper Subsets, NK Cells, and ILCs: The presence of various T helper (Th) subsets, NK cells, and ILCs, albeit in lower proportions, suggests a broader immune involvement beyond just cytotoxic and regulatory T cells. These cells play diverse roles in modulating immune responses, antigen presentation, and direct cytotoxicity (NK cells). While their individual proportions are small, their collective contribution to the overall immune contexture is important.

Clinical or Translational Implications

Understanding the precise composition of T cell subsets in the kidney cancer microenvironment has significant clinical implications.

• Prognostic Marker: An elevated ratio of T cell (Treg) to T cell (Cytotoxic) cells in the tumor microenvironment is often associated with a less favorable prognosis in various cancers, including kidney cancer, as it indicates a more immunosuppressive environment.
• Immunotherapy Response: The balance between different T cell subsets can influence the effectiveness of immunotherapies. For instance, checkpoint inhibitors aim to reactivate exhausted T cell (Cytotoxic) cells or counteract Treg-mediated suppression. Identifying samples with a high T cell (Treg) burden might inform strategies for combination therapies that target Tregs.
• Biomarker Development: The relative proportions of specific T cell subsets could serve as predictive biomarkers for response to specific treatments or as indicators of disease progression. Further research into the functional states of these T cells would provide deeper insights.

8. Macrophage Subset Population Analysis in Kidney Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot showing the relative proportions of different macrophage subsets (Macrophage (M1), Macrophage (M2A), Macrophage (M2B), Macrophage (M2C), and Macrophage (M2D)) across individual samples derived from both normal kidney tissue and kidney tumor tissue. The plot aims to identify potential shifts in macrophage polarization states within the tumor microenvironment compared to normal tissue, providing insights into the immune landscape of kidney cancer.

Visual Summary

The visualization displays the proportional distribution of macrophage subsets for five normal samples and nine tumor samples.

• Normal Samples: In the normal kidney tissue samples, Macrophage (M1) and Macrophage (M2A) subsets are the most prominent, with their combined proportion often exceeding 70-80%. Macrophage (M1) is dominant in some normal samples (e.g., SI_21256, SI_21255), while Macrophage (M2A) is also significantly represented in others (e.g., SI_18856, SI_22605). Macrophage (M2B), Macrophage (M2C), and Macrophage (M2D) subsets are present in smaller, more minor proportions. There is noticeable heterogeneity in the M1/M2A balance across individual normal samples.
• Tumor Samples: In contrast to normal samples, the tumor samples show a consistent and striking dominance of the Macrophage (M1) subset. In most tumor samples, Macrophage (M1) constitutes over 50% of the total macrophage population, frequently reaching proportions of 60-80% (e.g., SI_19703, SI_21561, SI_22604). The Macrophage (M2A) subset appears to be relatively reduced in proportion compared to normal samples. Macrophage (M2B), Macrophage (M2C), and Macrophage (M2D) subsets are still present but generally remain minor components within the tumor microenvironment macrophages. This suggests a significant shift towards an M1-dominant phenotype in the tumor setting.

Biological Interpretation

Macrophages are a critical component of the tumor microenvironment (TME) and play a dual role in cancer progression, being broadly classified into pro-inflammatory (M1-like) and anti-inflammatory/pro-tumorigenic (M2-like) phenotypes.

• M1 Macrophages: Typically associated with anti-tumor immunity, producing pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and reactive oxygen/nitrogen species that can directly kill tumor cells or enhance adaptive immune responses PubMed Search: M1 macrophage cancer.
• M2 Macrophages: Generally promote tumor growth, angiogenesis, metastasis, and immunosuppression, often referred to as Tumor-Associated Macrophages (TAMs). Different M2 subsets (M2A, M2B, M2C, M2D) have distinct functions, with M2D being particularly associated with pro-angiogenic and immunosuppressive roles in tumors PubMed Search: M2 macrophage cancer.

The prominent finding here is the consistent dominance of Macrophage (M1) in kidney tumor samples. This observation is noteworthy because in many solid tumors, there is often a shift towards M2-like macrophages (TAMs), which promote tumor progression and immune escape. The prevalence of M1 macrophages in these kidney tumor samples could indicate:

1. Strong Anti-Tumor Immune Response: The tumor microenvironment might be actively attempting to mount an M1-driven pro-inflammatory response against the cancer cells. This could represent an ongoing, albeit potentially insufficient, immune surveillance or response.
2. Specific Kidney Cancer Context: The specific molecular and cellular context of kidney cancer (e.g., clear cell renal cell carcinoma, a common subtype) may uniquely favor an M1-like macrophage polarization compared to other cancer types. Certain cytokines or signaling pathways within the kidney TME could be driving this M1 phenotype.
3. Heterogeneity and Subtype Specificity: It is also possible that the M1 classification here captures a spectrum of macrophage states, and some M1-like cells might co-exist with or transition into other phenotypes or might not be fully effective in tumor eradication despite their M1 signature.

The relative reduction of M2A macrophages in tumors compared to some normal samples, while M1 increases, suggests a potential shift in the inflammatory balance within the TME of kidney cancer. The minor presence of M2B, M2C, and M2D subsets indicates that while M1 is dominant, the TME still contains diverse macrophage populations that may contribute to various aspects of tumor-immune interaction.

Clinical or Translational Implications

The dominance of M1 macrophages in kidney tumor samples could have several clinical implications:

• Immunotherapy Response: Tumors with a higher proportion of M1 macrophages might be more responsive to certain immunotherapies that aim to enhance anti-tumor immunity, as M1 cells are generally associated with a more "hot" or inflamed tumor phenotype.
• Biomarker Potential: The M1/M2 ratio or the absolute proportion of M1 macrophages could potentially serve as a prognostic or predictive biomarker for kidney cancer patients, indicating the nature of the immune response within the tumor.
• Targeted Therapies: Understanding the specific factors driving M1 polarization in kidney cancer could lead to the development of novel therapeutic strategies that aim to sustain or augment the M1 phenotype, or to re-educate M2-like macrophages towards an M1-like, anti-tumorigenic state.

Further characterization of the functional state of these M1-dominant macrophages within the tumor is crucial to determine if they are fully functional in their anti-tumor role or if they represent an "exhausted" or ineffective M1-like state.

9. Differential Proportion of Macrophage (M2C) Subpopulation in Kidney Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a box plot illustrating the proportion of Macrophage (M2C) cells across 'normal' and 'tumor' conditions within kidney tissue. The purpose is to identify macrophage subsets that exhibit statistically significant differences in their representation between healthy and cancerous environments, as defined by the applied pval_cutoff of 0.1.

Visual Summary

The box plot shows the celltype proportion of Macrophage (M2C) cells.

• Condition Comparison: The proportion of Macrophage (M2C) cells is noticeably higher in the 'tumor' condition compared to the 'normal' condition.
• Median and Range: The median proportion of Macrophage (M2C) in tumor samples appears to be around 16%, with an interquartile range roughly spanning 12-20%. In contrast, the median proportion in normal samples is around 7-8%, with an interquartile range of about 7-9%.
• Statistical Significance: A p-value of 0.0584 is indicated, which is below the user-defined pval_cutoff of 0.1, suggesting a statistically significant difference (or strong trend towards significance) in the proportion of M2C macrophages between tumor and normal kidney tissues.
• Data Distribution: The individual data points (black dots) indicate variability within each group, with some outliers observed, particularly a low outlier in the 'normal' group and a high outlier in the 'tumor' group. The stripplot shows the individual sample proportions contributing to each box.

Biological Interpretation

Macrophages are critical components of the tumor microenvironment (TME), often differentiating into various phenotypes with distinct functions. M2 macrophages, including M2C, are generally associated with immunosuppression, tissue repair, angiogenesis, and tumor progression.

• M2C Macrophages in Tumor: The significantly increased proportion of Macrophage (M2C) cells in the 'tumor' condition suggests their recruitment and/or proliferation within the kidney cancer microenvironment. M2C macrophages (also known as deactivated macrophages or tumor-associated macrophages (TAMs) with M2-like properties) are known to contribute to tumor growth by promoting angiogenesis, extracellular matrix remodeling, and suppressing anti-tumor immune responses PubMed Search: M2C macrophages tumor microenvironment.
• Role in Kidney Cancer: In kidney cancer, the presence of specific macrophage subtypes can influence disease progression. An increased presence of M2C-like macrophages often correlates with a more immunosuppressive TME, potentially hindering effective anti-tumor immunity. This shift contributes to the tumor's ability to evade immune surveillance and grow unchecked.
• Contextualizing M2 Subtypes: While M1 macrophages are typically pro-inflammatory and anti-tumorigenic, M2 macrophages (including M2A, M2B, M2C, M2D) are broadly categorized as pro-tumoral. M2C macrophages are often induced by IL-10 or glucocorticoids and are characterized by high expression of CD163 and CD206, and reduced antigen presentation, contributing to chronic inflammation and immune tolerance GeneCards: CD163. Their elevated presence in the tumor implies a substantial contribution to the pro-tumorigenic landscape.

Clinical or Translational Implications

The significant increase of Macrophage (M2C) cells in kidney tumors has several potential clinical implications:

• Prognostic Marker: A higher proportion of M2C macrophages in tumor tissue might serve as a prognostic indicator for aggressive disease or poorer outcomes in kidney cancer patients, consistent with their role in promoting tumor progression and immune evasion.
• Therapeutic Target: Given their pro-tumoral functions, M2C macrophages represent a potential therapeutic target. Strategies aimed at depleting M2C macrophages, reprogramming them towards an M1-like phenotype, or inhibiting their pro-tumorigenic functions could be explored to enhance anti-tumor immunity and improve therapeutic responses in kidney cancer PubMed Search: macrophage reprogramming cancer therapy.
• Immunotherapy Response: The presence of an M2C-rich microenvironment could predict resistance to certain immunotherapies that rely on robust anti-tumor T cell responses, such as checkpoint blockade. Targeting M2C macrophages might therefore improve the efficacy of existing immunotherapeutic approaches.

10. Ploidy Distribution of Renal Epithelial Cells in Kidney Tissue Across Normal and Tumor Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the ploidy status (Diploid vs. Aneuploid) of Renal Epithelial cells, which have been identified as the resolved tumor-origin cell type, across individual samples from both 'normal' and 'tumor' kidney tissues. The results are visualized as stacked bar plots, with each bar representing a distinct sample and showing the proportion of Aneuploid and Diploid cells within the Renal Epithelial cell population for that sample.

Visual Summary

The bar plots distinctly separate cells based on their origin condition: 'normal' on the left and 'tumor' on the right.

• Normal Condition Samples: In all six 'normal' samples (e.g., SI_18856, SI_21256, SI_21255, SI_19704, SI_22605, SI_22369), Renal Epithelial cells are almost exclusively classified as Diploid (light yellow bars reaching 100%). This indicates a normal chromosome complement in healthy kidney epithelial cells.
• Tumor Condition Samples: A striking difference is observed in the 'tumor' samples (e.g., SI_18855, SI_19703, SI_22368, SI_18854, SI_21561, SI_22604, SI_23459).
  • The majority of Renal Epithelial cells in tumor samples are classified as Aneuploid (dark red bars).
  • For most tumor samples (SI_19703, SI_22368, SI_18854, SI_21561, SI_22604, SI_23459), nearly 100% of the Renal Epithelial cells are Aneuploid.
  • One tumor sample, SI_18855, shows a mixed population, with approximately 50-60% Aneuploid and 40-50% Diploid Renal Epithelial cells. This suggests heterogeneity within tumor samples, potentially indicating a subpopulation of diploid tumor cells, contaminating normal epithelial cells, or an earlier stage of chromosomal instability in that specific sample.

Biological Interpretation

The observed ploidy patterns strongly support the inference of Kidney Cancer and the identification of Renal Epithelial cells as the malignant population.

• Hallmark of Cancer: Aneuploidy, the condition of having an abnormal number of chromosomes, is a well-established hallmark of most human cancers, including kidney cancer. Normal somatic cells maintain diploidy to ensure proper gene dosage and cellular function. The consistent diploidy in Renal Epithelial cells from 'normal' samples serves as an important control, confirming the robustness of the ploidy assessment.
• Confirmation of Tumor-Origin Cell Type: The high prevalence of aneuploidy specifically within Renal Epithelial cells in the 'tumor' condition provides compelling evidence that these are indeed the transformed, cancerous cells. This aligns perfectly with the 'Resolved tumor-origin cell type' being 'Renal Epithelial cell' from the data context.
• Tumor Heterogeneity: The variation observed in sample SI_18855, where a substantial diploid population coexists with aneuploid cells, highlights potential inter-tumor or intra-tumor heterogeneity. This could be due to varying degrees of tumor purity, presence of non-malignant stromal or immune cells misclassified as epithelial, or biological differences in the evolutionary stage of aneuploidy acquisition among different tumors. The availability of CNV estimates in the AnnData supports the technical capability to detect these genomic alterations.

Clinical or Translational Implications

• Diagnostic and Prognostic Marker: Aneuploidy is a critical indicator of malignancy. Its presence in Renal Epithelial cells from tumor samples reinforces its potential as a diagnostic marker for kidney cancer. The extent of aneuploidy can also have prognostic implications, as higher levels of chromosomal instability are often associated with more aggressive tumors and worse patient outcomes.
• Targeting Aneuploid Cells: The distinct aneuploid profile of tumor cells compared to normal cells could present therapeutic opportunities. Strategies that specifically target cells with aneuploidy or the pathways driving chromosomal instability might selectively eliminate cancer cells while sparing healthy tissue.
• Understanding Tumor Evolution: The sample-level analysis reveals the heterogeneity of ploidy status, which is important for understanding tumor evolution and potential resistance mechanisms. The mixed population in sample SI_18855 suggests that not all tumor cells may be uniformly aneuploid, or that the aneuploid clone has not yet completely taken over, which could impact treatment response. Investigating such heterogeneous samples could provide insights into early events of tumor development or the presence of therapy-resistant diploid subpopulations.
• Further Characterization: These findings warrant further investigation into the specific chromosomal gains or losses (CNVs) within these aneuploid Renal Epithelial cells, which could uncover driver mutations or vulnerabilities specific to kidney cancer pathogenesis. PubMed search: Aneuploidy in cancer, diagnosis, prognosis

11. Cell-Cell Interaction Patterns in Normal and Kidney Tumor Microenvironments

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates significant cell-cell interaction (CCI) patterns using single-cell RNA-seq data from human kidney tissue, comparing 'normal' and 'tumor' conditions. The plot_cci_dots tool was used to visualize ligand-receptor interactions among specified cell types, including Renal Epithelial cells, Fibroblasts, Macrophages, T cell CD4+, and T cell CD8+. Interactions were evaluated based on p-value and mean expression, with a focus on identifying active communication networks within the tumor microenvironment (TME) that could inform therapeutic strategies or provide biological insights into kidney cancer progression.

Visual Summary

CCI for normal (Left Plot):

The dot plot for the 'normal' condition shows a highly restricted set of cell-cell interactions. Only autocrine interactions within 'Diploid Renal Epi' (Diploid Renal Epithelial cells) are displayed. These include ligand-receptor pairs such as APLP2_PIGR, PPIA_BSG, and ProstaglandinE2_byPTGES2_PTGER3. The dots indicate high significance (large size, low p-value) and moderate to high mean expression (yellow/green color) for these specific interactions. The scarcity of interactions suggests a relatively quiescent or stable cellular communication landscape in the normal kidney tissue, or that other interactions did not meet the stringent significance thresholds or were filtered by the n_pairs_to_show parameter.

CCI for tumor (Right Plot):

In stark contrast, the 'tumor' condition exhibits a vastly more complex and active network of cell-cell interactions. This plot reveals significant autocrine and paracrine communications involving 'Mac' (Macrophages) and 'Aneuploid Renal Epi' (Aneuploid Renal Epithelial cells, representing tumor cells).

• Autocrine Macrophage (Mac|Mac) interactions are prominent, featuring pairs like CCL3_CCR1, CCL20_CCR6, CD55_CD97, and IL10_IL10RB.
• Paracrine Macrophage to Tumor (Mac|Aneuploid Renal Epi) interactions are extensive, including APOE_TREM2_receptor, CCL3_CCR1, CCL20_CCR6, IL10_IL10RB, PLAUR_integrin_integrin_aVb3_complex, and ProstaglandinE2_byPTGES2_PTGER4.
• Paracrine Tumor to Macrophage (Aneuploid Renal Epi|Mac) interactions are also numerous, highlighting pairs such as CD55_ADGRE5, CDH1_CDH2, HBEGF_EGFR, ICAM1_integrin_aMb2_complex, LGALS9_HAVCR2, NAMPT_NOX_OSMR, SPP1_integrin_aV_complex, and several TNFSF-TNFRSF family interactions.
• Autocrine Tumor (Aneuploid Renal Epi|Aneuploid Renal Epi) interactions are also highly active, mirroring many of the paracrine interactions observed (e.g., CDH1_CDH2, HBEGF_EGFR, ICAM1_integrin_aMb2_complex, PLAUR_integrin_integrin_aVb3_complex, SPP1_integrin_aV_complex, TNFSF family).

The color intensity (log2(mean)) and dot size (-log10(p)) for many of these interactions are high, indicating strong and significant communication events. Notably, other target cell types (Fibroblast, T cell CD4+, T cell CD8+) do not appear to have prominent interactions that met the significance criteria and display limits in this visualization.

Biological Interpretation

The striking difference in CCI patterns between normal and tumor conditions underscores the profound reorganization of cellular communication within the kidney cancer microenvironment. The transition from a largely quiescent state to a highly active interactome involving macrophages and aneuploid renal epithelial cells is characteristic of cancer progression.

1. Macrophage Infiltration and Activation: The extensive involvement of Macrophages in the tumor context, both in autocrine signaling (Mac|Mac) and in bidirectional communication with tumor cells, is highly significant. Tumor-associated macrophages (TAMs) are well-known contributors to tumor growth, angiogenesis, metastasis, and immunosuppression in kidney cancer and other malignancies PubMed search: Tumor-associated macrophages kidney cancer.
   • Chemokine Signaling (e.g., CCL3_CCR1, CCL20_CCR6): These interactions suggest active recruitment and retention of macrophages within the TME, as well as their potential role in modulating the inflammatory landscape.
   • Immunosuppressive Signaling (e.g., IL10_IL10RB): Interleukin-10 (IL-10) is a potent immunosuppressive cytokine. Macrophage-derived IL-10 can promote tumor growth by dampening anti-tumor immune responses.
   • Pro-tumorigenic Adhesion/Migration (e.g., PLAUR_integrin_integrin_aVb3_complex): Plasminogen activator, urokinase receptor (PLAUR/uPAR) and integrins are often involved in cell adhesion, migration, and extracellular matrix remodeling, contributing to tumor invasion and metastasis.
2. Tumor Cell Growth and Survival Pathways: The autocrine and paracrine interactions involving Aneuploid Renal Epithelial cells highlight pathways crucial for tumor maintenance and progression.
   • Growth Factor Signaling (e.g., HBEGF_EGFR): Heparin-binding EGF-like growth factor (HBEGF) binding to its receptor, EGFR, is a potent mitogenic pathway frequently hyperactivated in cancers, driving cell proliferation and survival. GeneCards: EGFR
   • Adhesion and Invasion (e.g., SPP1_integrin_aV_complex): Secreted phosphoprotein 1 (SPP1, also known as Osteopontin) is frequently overexpressed in various cancers and interacts with integrins to promote tumor cell adhesion, migration, invasion, and angiogenesis, while also influencing immune cell function. GeneCards: SPP1
   • TNF Superfamily Interactions (e.g., TNFSF12_TNFRSF1A, TNFSF10_TNFRSF10B, TNFSF14_TNFRSF1B): Members of the TNF superfamily regulate diverse cellular processes including apoptosis, cell survival, inflammation, and immunity. Their dysregulation in the TME can contribute to immune evasion and tumor progression. PubMed search: TNF superfamily cancer
3. Tumor-Macrophage Crosstalk: The bidirectional communication between Aneuploid Renal Epithelial cells and Macrophages suggests a co-dependent relationship. Tumor cells likely educate macrophages towards a pro-tumorigenic phenotype, while macrophages, in turn, provide growth factors and an immunosuppressive environment that favors tumor survival and expansion. The absence of prominent interactions with Fibroblasts and T cells in this visualization suggests that Macrophages and Renal Epithelial cells are the dominant players in the most significant communication axes identified here.

Clinical or Translational Implications

The identified cell-cell interaction patterns in the kidney tumor microenvironment offer several important clinical and translational implications, particularly for therapeutic target prioritization and experimental validation:

Therapeutic Targeting of Growth and Survival Pathways:

• EGFR inhibition: Given the prominent HBEGF_EGFR interaction, EGFR inhibitors, which are already approved for other cancers, could be explored for kidney cancer patients with similar interaction patterns.
• SPP1-integrin axis blockade: Targeting SPP1 or its cognate integrin receptors (e.g., integrin alpha-V) could disrupt multiple pro-tumorigenic processes, including tumor cell migration, invasion, and immune modulation.

Modulation of the Tumor Microenvironment via Macrophages:

• Macrophage reprogramming/depletion: The extensive involvement of macrophages highlights their potential as therapeutic targets. Strategies to deplete TAMs, or to reprogram them from a pro-tumorigenic M2-like phenotype to an anti-tumorigenic M1-like phenotype, could be beneficial.
• Targeting chemokine axes: Blocking CCL3-CCR1 or CCL20-CCR6 signaling could reduce macrophage recruitment to the tumor, thereby mitigating their pro-tumorigenic effects.
• Immunosuppression reversal: Inhibiting IL10-IL10RB signaling could help reverse macrophage-mediated immunosuppression and enhance anti-tumor immune responses.

• Biomarker Discovery: The identified ligand-receptor pairs could serve as potential diagnostic or prognostic biomarkers. Elevated expression of these interacting partners or specific interaction patterns might correlate with disease progression, metastasis, or response to specific therapies.
• Combination Therapies: The complexity of the tumor interactome suggests that single-agent therapies targeting only one pathway might have limited efficacy. Combining therapies that disrupt multiple key interactions, for example, an EGFR inhibitor with a macrophage-targeting agent, could lead to more robust anti-tumor responses.

These findings provide a basis for further experimental validation, potentially using in vitro co-culture systems or in vivo models, to confirm the functional significance of these specific cell-cell interactions in kidney cancer progression and to test the efficacy of targeting these pathways.

12. Condition-Specific Cell-Cell Interaction Patterns in Kidney Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates condition-specific cell-cell interaction (CCI) patterns involving Renal Epithelial cells, major immune cells (Macrophages, T cells), and stromal cells (Smooth muscle cells, Fibroblasts) in Kidney tissue, comparing 'normal' and 'tumor' conditions. The dot plot visualizes the strength and significance of these interactions across individual samples, providing insights into the altered cellular communication landscape in kidney cancer. The max_n_items_per_group parameter was set to 60, displaying the most significant interactions for each condition.

Visual Summary

The dot plot displays cell-cell interaction (CCI) strength (color intensity, redder indicates stronger scaled log strength) and significance (dot size, larger indicates lower p-value) for individual samples. Samples are grouped by condition ('normal' on the left, 'tumor' on the right). The x-axis lists specific ligand-receptor pairs and the interacting cell types (e.g., gene_A-gene_B | cell_A | cell_B).

Key visual observations include:

• Differential Interaction Density: The 'tumor' condition exhibits a significantly higher density and strength of cell-cell interactions compared to the 'normal' condition. Most tumor samples show numerous dark red, large dots, indicating strong and highly significant interactions. In contrast, 'normal' samples generally show fewer and weaker interactions, with only a subset of normal samples (e.g., SI_18856, SI_19704, SI_21255) displaying prominent interactions.
• Prominent Cell-Cell Pairs in Tumor: Interactions involving Renal.Epi (Aneuploid) cells with Macrophage and Smooth muscle cell (SMC) populations are particularly abundant and strong in the tumor microenvironment. Interactions involving T cell CD8+ are also observed, primarily with Renal.Epi (Aneuploid) and Macrophage cells in the tumor condition.

Specific Interaction Categories:

• Integrin-mediated interactions (e.g., SPP1-integrin, FN1-integrin, COL-integrin, L1CAM-integrin) are highly prevalent and strong in the tumor condition, often involving Renal.Epi (Aneuploid) with Macrophage or SMC.
• Chemokine signaling pathways (e.g., CXCL12-CXCR4, CXCL14-CXCR4, CCL3-CCR1, CCL5-CCR1) are also significantly activated in tumor samples, predominantly between Renal.Epi (Aneuploid) and Macrophage cells.
• Growth factor/cytokine signaling (e.g., AREG-EGFR, IL1B-IL1_receptor, PPIA-BSG) shows increased activity in the tumor context.

• Ploidy Status: The cell types in the tumor condition are primarily Renal.Epi (Aneuploid), consistent with the overall dataset context indicating a substantial aneuploid population and 'Renal Epithelial cell' as the resolved tumor-origin cell type. Normal interactions predominantly involve Renal.Epi (Dip) (Diploid).

Biological Interpretation

The observed shifts in CCI patterns provide critical insights into the kidney cancer tumor microenvironment (TME), highlighting how tumor cells reprogram their communication with immune and stromal cells to support growth, invasion, and immune evasion.

Interactions in the Normal Condition

In the normal kidney, CCIs typically maintain tissue homeostasis, regulate immune surveillance, and support tissue repair. The interactions observed, while less pervasive than in tumor, likely represent these physiological roles:

Renal Epithelial (Diploid) – Macrophage Interactions:

• APOE-TREM2_receptor: APOE (Apolipoprotein E) interactions with TREM2 (Triggering Receptor Expressed on Myeloid cells 2) are involved in lipid metabolism, debris clearance, and modulation of inflammatory responses in macrophages. In normal tissue, this may contribute to tissue maintenance and resolution of minor injury.
• AREG-EGFR: Amphiregulin (AREG) binding to EGFR (Epidermal Growth Factor Receptor) plays a role in epithelial cell proliferation, differentiation, and tissue repair. This interaction is essential for healthy kidney maintenance.
• CXCL14-CXCR4: CXCL14 is a chemokine that can act as a homeostatic chemokine, influencing immune cell trafficking and maintaining tissue integrity.

Renal Epithelial (Diploid) – Smooth Muscle Cell Interactions:

• ProstaglandinE2_byPTGES3_PTGER2: Prostaglandin E2 (PGE2) signaling regulates local inflammation, blood flow, and tissue remodeling. In normal kidney, this axis contributes to physiological responses.
• COL6A1_integrin_a2b1_complex: Interactions between Collagen VI (COL6A1) and integrin complexes are vital for cell-extracellular matrix adhesion, maintaining tissue structure, and mechanotransduction in healthy kidney.

Interactions in the Tumor Condition

The tumor microenvironment shows a dramatic increase in the complexity and strength of interactions, particularly involving aneuploid Renal Epithelial cells and various immune and stromal components, reflecting the dynamic and pro-tumorigenic cellular crosstalk.

1. Renal Epithelial (Aneuploid) – Macrophage Interactions

Macrophages, especially tumor-associated macrophages (TAMs), are key players in the TME, often promoting tumor growth and immune suppression. Many interactions here suggest a highly reprogrammed macrophage phenotype.

SPP1-integrin_a4b1_complex | Renal.Epi (Aneuploid) | Mac:

• Signaling/Mechanism: Secreted phosphoprotein 1 (SPP1, also known as Osteopontin) is an extracellular matrix protein that binds to integrin receptors, including α4β1. This interaction promotes cell adhesion, migration, survival, and angiogenesis. In macrophages, SPP1 can drive M2-like polarization, fostering an immunosuppressive and pro-tumorigenic phenotype.
• Biological Role in Kidney Cancer: Elevated SPP1 expression is associated with tumor progression, metastasis, and poor prognosis in many cancers, including kidney cancer. It facilitates tumor cell invasion and creates a permissive microenvironment.
• Therapeutic Potential: Targeting SPP1 or its integrin receptors could inhibit tumor progression and modulate the immune response.
• Relevant Agents: Antibodies neutralizing SPP1 or integrin α4β1 inhibitors are under investigation in preclinical and clinical settings.
• GeneCards: SPP1
• PubMed search: SPP1 integrin cancer therapy

CXCL12-CXCR4 | Renal.Epi (Aneuploid) | Mac:

• Signaling/Mechanism: The CXCL12-CXCR4 axis is a critical chemokine signaling pathway. CXCL12 (stromal cell-derived factor 1) binds to its receptor CXCR4, activating G protein-coupled signaling pathways (e.g., PI3K/Akt, MAPK) that promote cell migration, proliferation, angiogenesis, and survival.
• Biological Role in Kidney Cancer: This axis is a major driver of tumor cell metastasis to distant organs, recruitment of immune-suppressive cells (like TAMs and myeloid-derived suppressor cells), and angiogenesis within the TME.
• Therapeutic Potential: CXCR4 is a well-validated therapeutic target in cancer.
• Relevant Agents: Plerixafor (a CXCR4 antagonist) is FDA-approved for stem cell mobilization and is being investigated in various cancers to inhibit metastasis and enhance immunotherapy.
• GeneCards: CXCL12
• GeneCards: CXCR4

AREG-EGFR | Renal.Epi (Aneuploid) | Mac:

• Signaling/Mechanism: Amphiregulin (AREG) is an EGFR ligand. Its binding to EGFR activates downstream pathways (Ras/MAPK, PI3K/Akt, STAT) that regulate cell proliferation, survival, and differentiation. While primarily known for epithelial cell growth, this interaction can also influence macrophage behavior and create a pro-tumorigenic feedback loop.
• Biological Role in Kidney Cancer: Upregulated EGFR signaling is common in many cancers, driving uncontrolled cell growth and resistance to therapy. AREG overexpression can promote tumor invasiveness and angiogenesis.
• Therapeutic Potential: EGFR is a highly targeted receptor in oncology.
• Relevant Agents: EGFR inhibitors (e.g., Erlotinib, Gefitinib, Osimertinib) and anti-EGFR monoclonal antibodies (e.g., Cetuximab, Panitumumab) are widely used in cancer therapy.

LGALS3-MERTK | Renal.Epi (Aneuploid) | Mac:

• Signaling/Mechanism: Galectin-3 (LGALS3) is a lectin that can bind to various glycoproteins. MERTK (Mer Tyrosine Kinase) is a receptor tyrosine kinase primarily expressed on phagocytes, involved in efferocytosis (clearance of apoptotic cells) and immune suppression. Activation of MERTK promotes anti-inflammatory and immunosuppressive responses.
• Biological Role in Kidney Cancer: This interaction could contribute to immune evasion by promoting MERTK-mediated efferocytosis of apoptotic tumor cells by macrophages and inducing an immunosuppressive phenotype in TAMs. Galectin-3 itself has diverse roles in tumor progression, including cell adhesion, proliferation, and immune modulation.
• Therapeutic Potential: MERTK inhibitors are emerging as potential immunotherapeutic agents, aiming to reverse immune suppression in the TME. Galectin-3 inhibitors are also in development.
• GeneCards: LGALS3
• GeneCards: MERTK

Other Noteworthy Macrophage Interactions:

• CCL3-CCR1, CCL5-CCR1: These chemokine interactions further contribute to the recruitment and activation of immune cells, potentially shaping the inflammatory and immunosuppressive landscape.
• IL1B_IL1_receptor: Interleukin-1 beta (IL1B) is a potent pro-inflammatory cytokine that can promote tumor growth, angiogenesis, and metastasis by activating its receptor.
• THBS1-CD36: Thrombospondin-1 (THBS1) is an anti-angiogenic and pro-TGF-β activating protein, while CD36 is a fatty acid transporter. This interaction can influence lipid metabolism in the TME and macrophage function, impacting angiogenesis and immune responses.

2. Renal Epithelial (Aneuploid) – T cell CD8+ Interactions

While T cell CD8+ cells are crucial anti-tumor effectors, their interactions in the tumor context might include those that subvert their function or reflect a dysfunctional state.

CD44 -- Mac | Renal.Epi (Aneuploid) | T CD8+:

• Note on label ambiguity: The interaction "CD44 -- Mac" with "Renal.Epi (Aneuploid) | T CD8+" is unusually formatted. "Mac" is not a standard gene symbol. Assuming this denotes an interaction involving CD44 on one cell and a Macrophage-associated partner on another cell, mediating communication between Renal Epithelial (Aneuploid) and T CD8+ cells.
• Signaling/Mechanism: CD44 is a transmembrane glycoprotein involved in cell adhesion, migration, and signal transduction, often acting as a receptor for hyaluronan. It plays roles in immune cell activation and trafficking.
• Biological Role in Kidney Cancer: CD44 is frequently overexpressed in cancer cells and cancer stem cells, contributing to tumor progression, metastasis, and resistance to therapy. Interactions involving CD44 can modulate T cell activation or exhaustion.
• Therapeutic Potential: CD44 has been explored as a therapeutic target, particularly for cancer stem cells.
• GeneCards: CD44

3. Renal Epithelial (Aneuploid) – Smooth Muscle Cell (SMC) Interactions

The stromal compartment, including SMCs (often associated with perivascular or myofibroblastic phenotypes), profoundly influences tumor behavior.

FN1_integrin_aVb1_complex | Renal.Epi (Aneuploid) | SMC:

• Signaling/Mechanism: Fibronectin 1 (FN1) is a major component of the extracellular matrix (ECM) and interacts with integrins, including αVβ1. This interaction is critical for cell adhesion, migration, proliferation, and tissue remodeling.
• Biological Role in Kidney Cancer: Dysregulated ECM components like FN1 and their integrin receptors are hallmarks of the tumor microenvironment, promoting tumor cell invasion, metastasis, and supporting angiogenesis. SMCs contribute to this remodeled stroma.
• Therapeutic Potential: Targeting integrin-FN1 interactions can disrupt tumor-stroma crosstalk and inhibit tumor progression.
• Relevant Agents: Integrin inhibitors, though challenging, are actively researched.

THBS1_CD36 | Renal.Epi (Aneuploid) | SMC:

• Signaling/Mechanism: Thrombospondin-1 (THBS1) is a matricellular protein that modulates cell-matrix interactions and influences angiogenesis and immune responses. CD36 is a fatty acid translocase and scavenger receptor. This interaction can regulate lipid metabolism and pro-angiogenic or anti-angiogenic signaling within the TME.
• Biological Role in Kidney Cancer: THBS1 is complex, sometimes anti-angiogenic, but can also contribute to immune suppression via TGF-β activation. CD36 overexpression in tumor cells or stromal cells can support tumor growth by facilitating fatty acid uptake, particularly in nutrient-deprived TMEs.
• Therapeutic Potential: Targeting CD36 or THBS1 could disrupt metabolic adaptations of tumor cells or modulate angiogenesis.
• GeneCards: THBS1
• GeneCards: CD36

Clinical or Translational Implications

The profound differences in cell-cell interaction patterns between normal and tumor kidney tissue offer several clinical and translational implications for Kidney Cancer:

1. Biomarker Discovery: The highly specific and upregulated CCIs in tumor samples, such as SPP1-integrin or CXCL12-CXCR4, could serve as prognostic biomarkers, indicating disease aggressiveness or recurrence risk. They might also be detectable in liquid biopsies as circulating interaction components.
2. Therapeutic Target Identification: The identified interactions represent promising therapeutic targets. Inhibiting key pro-tumorigenic axes (e.g., CXCL12-CXCR4 to reduce metastasis and immune suppression; SPP1-integrin to block invasion) could offer novel therapeutic strategies or improve existing ones.
3. Combination Therapies: Given the complex interplay, combination therapies targeting multiple key interaction pathways (e.g., an EGFR inhibitor combined with a CXCR4 antagonist) could be more effective in overcoming resistance and inhibiting tumor progression.
4. Immunotherapy Sensitization: Interactions like LGALS3-MERTK that contribute to immune evasion could be targeted to re-sensitize kidney cancer to immunotherapies, potentially improving response rates to checkpoint inhibitors.
5. Understanding Treatment Resistance: Studying these interactions in the context of treatment response could reveal mechanisms of resistance to current therapies, guiding the development of salvage regimens.
6. Drug Repurposing: Existing drugs that target components of these pathways (e.g., EGFR inhibitors, CXCR4 antagonists) could be explored for their efficacy in kidney cancer. New drugs specifically designed to disrupt these identified tumor-specific CCIs could also be developed.

13. Condition-Specific Cell-Cell Interactions in Kidney Cancer Involving Immune and Cell Cycle Pathways

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies significant cell-cell interactions (CCI) involving Renal Epithelial cells, major immune cells (Myeloid, T, B, Mast), and stromal cells (Endothelial, Stromal) in kidney tissue, focusing on genes related to immune checkpoints and cell cycle pathways. The CCIs were compared between 'normal' and 'tumor' conditions using single-cell RNA-seq data. The dot plot visualizes the strength (scaled log strength, color intensity) and significance (-log10(p), dot size) of these interactions across different samples and conditions. The analysis specifically highlights interactions that differ significantly between conditions, providing insight into the dysregulated cellular communication network in kidney cancer.

Visual Summary

The dot plot displays a clear condition-specific pattern of cell-cell interactions.

• Normal Condition: Interactions are observed primarily within certain samples (e.g., SI_18856, SI_19704, SI_21255, SI_22369, SI_22605, SI_18854, SI_18855). These interactions largely involve Diploid Renal Epithelial cells (Renal.Epi (Dip)) with Macrophages (Mac), Endothelial cells (Endo), and Smooth Muscle Cells (SMC). Prominent interactions include those involving TGFB and integrin complexes (e.g., TGFB3_integrin_aVB6_complex).
• Tumor Condition: A distinctly different and generally more robust pattern of interactions emerges. Most notably, a new set of interactions involving Aneuploid Renal Epithelial cells (Renal.Epi (AneuP)) becomes highly active and significant across multiple tumor samples (e.g., SI_18854, SI_18855, SI_19703, SI_21561, SI_22368, SI_22604, SI_23459, SI_23843).
  • Interactions involving the EGFR family (AREG_EGFR, EREG_EGFR, HBEGF_EGFR, TGFA_EGFR) are predominantly and strongly active in the tumor condition. These involve Aneuploid Renal Epithelial cells interacting with Macrophages, Endothelial cells, and Smooth Muscle Cells.
  • Immune signaling interactions such as IFNG_Type_II_IFNR (involving T CD8+ cells and Aneuploid Renal Epithelial cells) and CD86_CD28 (between Macrophages and T CD8+ cells) are specifically enriched and highly significant in the tumor microenvironment.
  • Interactions involving TGF-beta receptors (TGFB1_TGFbeta_receptor1, TGFB2_TGFbeta_receptor2, TGFB3_TGFbeta_receptor3) with Aneuploid Renal Epithelial cells also show increased activity in tumor samples compared to normal.
• P-value and Strength: Dot size, representing the negative logarithm of the p-value (-log10(p)), and dot color intensity, representing scaled log strength, indicate many highly significant and strong interactions specifically in the tumor condition. The max_n_items_per_group setting (60) ensures that a comprehensive set of the most significant interactions is displayed for each condition.

Biological Interpretation

The observed condition-specific CCI patterns provide critical insights into the kidney cancer microenvironment, highlighting altered communication pathways that drive tumor progression and immune evasion. The involvement of 'Renal Epithelial cell (AneuP)' strongly suggests these are malignant cells.

Condition-Specific Interaction Patterns

The striking difference in CCI profiles between normal and tumor conditions underscores the profound reorganization of intercellular communication in kidney cancer. The shift from primarily basal stromal-epithelial interactions in normal tissue to complex networks involving aneuploid renal epithelial cells, immune cells, and stromal components in tumors reflects the dynamic and pathogenic tumor microenvironment.

Key Interactions in Tumor Microenvironment

1. EGFR Family Ligand-Receptor Interactions

• Associated Signaling Pathways and Mechanisms: Interactions involving EGFR and its ligands (AREG, EREG, HBEGF, TGFA) are highly active in the tumor condition, primarily between Macrophages, Endothelial cells, and Smooth Muscle Cells, and Aneuploid Renal Epithelial cells. EGFR signaling is a crucial pathway in cancer, promoting cell proliferation, survival, angiogenesis, and metastasis. Upon ligand binding, EGFR activates downstream pathways such as the RAS/RAF/MAPK pathway and the PI3K/AKT/mTOR pathway, which directly influence cell cycle progression (e.g., via MYC, CCND1, CDK4/6) and inhibit apoptosis. EGFR is a known oncogene, and its overexpression or constitutive activation is common in various cancers, including renal cell carcinoma.
  • GeneCards: EGFR: https://www.genecards.org/cgi-bin/carddisp.pl?gene=EGFR
• Potential as a Therapeutic Target: The robust activation of EGFR signaling in the tumor highlights its role as a key driver of kidney cancer growth and progression. Targeting EGFR can disrupt tumor cell proliferation, survival, and communication with the tumor microenvironment.
• Relevant Therapeutic Agents: Tyrosine kinase inhibitors (TKIs) like gefitinib, erlotinib, afatinib, and osimertinib (though more common in lung cancer, EGFR is a pan-cancer target) are established EGFR inhibitors. Monoclonal antibodies such as cetuximab and panitumumab also target EGFR.

2. TGF-beta Family Signaling

• Associated Signaling Pathways and Mechanisms: While TGF-beta interactions (TGFB1, TGFB2, TGFB3 with their receptors) are present in both normal and tumor conditions, their specific patterns and cellular partners change. In the tumor, significant interactions are observed between Aneuploid Renal Epithelial cells and Endothelial/Smooth Muscle Cells, as well as Macrophages. TGF-beta signaling is pleiotropic, acting as a tumor suppressor in early stages but promoting tumor progression, immune suppression, angiogenesis, and metastasis in advanced cancers. It activates SMAD-dependent and non-SMAD pathways, influencing cell differentiation, proliferation, and extracellular matrix remodeling. TGF-beta's role in epithelial-mesenchymal transition (EMT) is critical for metastasis, and it directly contributes to the immune suppressive microenvironment by inhibiting anti-tumor immune responses.
  • PubMed Search: TGF-beta cancer therapy: https://pubmed.ncbi.nlm.nih.gov/?term=TGF-beta+cancer+therapy
• Potential as a Therapeutic Target: Given its context-dependent role, targeting TGF-beta signaling in the tumor microenvironment can potentially reverse immune suppression and inhibit tumor progression.
• Relevant Therapeutic Agents: Clinical trials are investigating various TGF-beta inhibitors, including neutralizing antibodies (e.g., fresolimumab, bintrafusp alfa), ligand traps, and small molecule inhibitors of the TGF-beta receptor I kinase (e.g., galunisertib, vactosertib).

3. Immune Signaling Pathways

Associated Signaling Pathways and Mechanisms

• IFN-gamma Signaling (IFNG_Type_II_IFNR): Strong interactions are observed between T CD8+ cells and Aneuploid Renal Epithelial cells via the IFN-gamma receptor in the tumor condition. IFN-gamma is a critical cytokine produced by activated T cells and NK cells, playing a central role in anti-tumor immunity by enhancing MHC expression, activating macrophages, and inducing apoptosis in tumor cells. However, tumor cells can develop resistance mechanisms or exploit IFN-gamma signaling to upregulate immune checkpoints like PD-L1 (CD274), thereby leading to immune evasion.
  • GeneCards: IFNGR1: https://www.genecards.org/cgi-bin/carddisp.pl?gene=IFNGR1
• CD28-CD86 Co-stimulation: Significant interactions between Macrophages (CD86) and T CD8+ cells (CD28) are evident in the tumor. The CD28-CD86 interaction provides a critical co-stimulatory signal required for full T cell activation and proliferation, alongside the primary signal from the T cell receptor. Dysregulation of this pathway, or the balance with co-inhibitory signals (e.g., CTLA-4/CD80/CD86, PD-1/PD-L1), can lead to T cell anergy or exhaustion in the tumor microenvironment, contributing to immune evasion.
  • UniProt: CD28: https://www.uniprot.org/uniprotkb/P10747/entry
  • UniProt: CD86: https://www.uniprot.org/uniprotkb/P42081/entry

Potential as a Therapeutic Target

• IFN-gamma pathway: While IFN-gamma itself can be therapeutic, its potential for inducing immune checkpoint expression needs to be considered. Understanding the downstream effects in specific tumor types is crucial. Modulating this pathway could involve enhancing its anti-tumor effects or countering resistance mechanisms.
• CD28-CD86: This co-stimulatory pathway is a classical target for modulating T cell activity. Strategies might involve agonists to enhance T cell activation (in combination with checkpoint blockade) or antagonists in autoimmune settings (less likely for cancer therapy, but principle applies).

Relevant Therapeutic Agents

• IFN-gamma: Recombinant IFN-gamma (e.g., Actimmune) has been used in some cancers, but its efficacy in kidney cancer is limited and requires careful consideration of its immunomodulatory effects.
• CD28-CD86: Abatacept (CTLA-4-Ig) blocks CD28-CD86 interaction and is used in autoimmune diseases. For cancer, the focus is often on enhancing T cell co-stimulation or blocking co-inhibition. While not directly visible in the plot, the presence of these immune interactions points to the broader importance of immune checkpoints like PDCD1 (PD-1) and CD274 (PD-L1), which are in the target gene list. Therapies targeting these pathways, such as PD-1 inhibitors (e.g., nivolumab, pembrolizumab) and PD-L1 inhibitors (e.g., atezolizumab, durvalumab, avelumab), are standard in kidney cancer. CD86 is also a ligand for CTLA-4, another immune checkpoint.

Clinical or Translational Implications

The findings suggest several actionable targets for kidney cancer therapy:

• Therapeutic Targeting of EGFR Signaling: The strong activation of EGFR signaling in aneuploid renal epithelial cells and their surrounding stromal/immune cells in tumors indicates that EGFR is a significant driver in kidney cancer. EGFR inhibitors could be beneficial, potentially slowing tumor growth and progression by blocking proliferation signals and communication within the tumor microenvironment. Combinatorial therapies involving EGFR inhibitors with other agents (e.g., anti-angiogenic drugs or immunotherapy) might be more effective.
• Therapeutic Targeting of TGF-beta Signaling: The altered TGF-beta interactions in the tumor microenvironment, particularly those involving aneuploid renal epithelial cells, highlight its role in immune suppression and tumor progression. Targeting TGF-beta signaling could help to remodel the tumor microenvironment, enhance anti-tumor immunity, and reduce metastasis.
• Therapeutic Targeting of Immune Co-stimulation/Checkpoint Pathways: The increased activity of IFNG signaling and CD28-CD86 co-stimulation in the tumor context, particularly involving T CD8+ cells, underscores the active but potentially dysregulated immune response. While IFNG is pro-inflammatory, tumor cells can exploit it. The prominence of CD28-CD86 interactions suggests the importance of robust T cell activation in the tumor microenvironment. Given that related immune checkpoint genes (PDCD1, CD274) were part of the initial query, these observations reinforce the rationale for immune checkpoint blockade (e.g., anti-PD-1/PD-L1, anti-CTLA-4) to unleash anti-tumor T cell responses in kidney cancer. Further investigation into the balance of co-stimulatory and co-inhibitory signals will be crucial for optimizing immunotherapeutic strategies.

14. Renal Epithelial Cell Condition-Specific Surfaceome Markers: Potential Therapeutic Targets in Kidney Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies surfaceome markers differentially expressed in Renal Epithelial cells across 'normal' and 'tumor' conditions within a kidney tissue single-cell RNA-seq dataset. The goal is to highlight established therapeutic targets and potential novel targets based on their condition-specific expression profiles, particularly focusing on markers enriched in the tumor condition. The dot plot visualizes the mean expression level (color intensity) and the fraction of cells expressing the marker (dot size) for each gene across different samples (SI_XXXXX) grouped by condition.

Visual Summary

The dot plot, titled "Renal Epithelial cell condition-specific markers," effectively displays surfaceome gene expression patterns.

• Normal-enriched markers (Top Left Quadrant): A distinct group of markers, including EPCAM, CLDN10, DPEP1, GPR160, BCAM, ITM2C, and TACSTD2, show high mean expression and high cell fraction in several normal samples (e.g., SI_18856, SI_21256, SI_22605). These markers are generally expressed at very low levels or not at all in tumor samples.
• Tumor-enriched markers (Bottom Right Quadrant): A large cluster of markers exhibits high mean expression and high cell fraction predominantly in tumor samples (e.g., SI_18854, SI_22604, SI_18855, SI_19703, SI_23459, SI_21561, SI_22368). These include numerous Major Histocompatibility Complex (MHC) class II genes (HLA-DRA, HLA-DRB1, HLA-DPA1, HLA-DPB1, HLA-DQB1, HLA-DMA, HLA-DRB5), as well as genes like CA12, C5orf15, MYADM, SLC38A1, TNFRSF1A, EGFR, BST2, EMP3, TNFRSF14, TMED7, TSPAN4, CD47, MET, CDH5, ICAM1, CD70, SGCB, TP53I13, SERINC3, and several SLC family members (SLC2A1, SLC2A8, SLC2A3, SLC12A7, SEZ6L2). These markers are largely absent or lowly expressed in normal renal epithelial cells.
• Variability within conditions: While clear condition-specific patterns emerge, there is some heterogeneity among samples within both normal and tumor groups. For instance, some normal samples show higher expression of certain "normal-specific" markers than others, and similarly for tumor samples.
• Quantitative metrics: The plot utilizes nz_pct_score and nz_pct FC cutoffs for marker selection, ensuring that identified markers are not only expressed but also significantly enriched in one condition over others. The normal_vs_others comparison used nz_pct_score >= 0.183 and nz_pct FC > 1.31, while tumor_vs_others used stricter criteria: nz_pct_score >= 0.25 and nz_pct FC > 1.75.

Biological Interpretation

The analysis reveals distinct surfaceome expression signatures for normal and tumor Renal Epithelial cells, providing insights into potential changes associated with kidney cancer.

Markers Enriched in Normal Renal Epithelial Cells

Markers highly expressed in normal Renal Epithelial cells likely represent components essential for healthy kidney function and epithelial cell identity.

• EPCAM (Epithelial Cell Adhesion Molecule): Highly expressed in many normal renal epithelial cells. EPCAM is a homotypic cell adhesion molecule commonly used as a general epithelial cell marker. Its role includes cell adhesion, proliferation, and differentiation. While generally associated with epithelial integrity, its expression can be altered in certain cancers, but here it appears more consistently with normal cells. GeneCards: EPCAM
• CLDN10 (Claudin 10): A member of the claudin family, forming tight junctions that regulate paracellular permeability. Its specific expression in renal epithelial cells suggests a role in maintaining kidney filtration and reabsorption barrier function. UniProt: CLDN10
• DPEP1 (Dipeptidase 1): Also known as renal dipeptidase, it is expressed on the brush border of renal proximal tubule cells and plays a role in metabolizing dipeptides and glutathione. Its presence is consistent with the metabolic functions of healthy kidney epithelial cells. GeneCards: DPEP1

The downregulation of these markers in tumor cells could indicate dedifferentiation, loss of normal epithelial architecture, or a shift in cellular identity during malignant transformation.

Markers Enriched in Tumor Renal Epithelial Cells

The array of markers highly expressed in tumor Renal Epithelial cells points to various mechanisms involved in cancer progression, immune evasion, and metabolic reprogramming.

Established Therapeutic Targets

EGFR (Epidermal Growth Factor Receptor)

• Signaling Pathways/Mechanisms: EGFR is a receptor tyrosine kinase that, upon ligand binding (e.g., EGF, TGF-α), activates downstream signaling cascades such as the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways, promoting cell proliferation, survival, migration, and angiogenesis. Overexpression or activating mutations of EGFR are common in many cancers, leading to uncontrolled growth.
• Relevant Therapeutic Agents: Tyrosine Kinase Inhibitors (TKIs) like Erlotinib, Gefitinib, Osimertinib; monoclonal antibodies such as Cetuximab and Panitumumab. These agents target the receptor's activity or block ligand binding.
• Supporting Evidence: EGFR is a well-established oncogene and therapeutic target across various cancers, including subsets of kidney cancer. PubMed: EGFR in renal cell carcinoma therapy

MET (MET Proto-Oncogene, Receptor Tyrosine Kinase)

• Signaling Pathways/Mechanisms: MET is a receptor tyrosine kinase for Hepatocyte Growth Factor (HGF). HGF/MET signaling plays crucial roles in embryogenesis, wound healing, and tissue regeneration. In cancer, aberrant MET activation promotes cell growth, survival, invasion, metastasis, and angiogenesis.
• Relevant Therapeutic Agents: MET inhibitors like Cabozantinib, Crizotinib, Tepotinib. Cabozantinib is approved for advanced renal cell carcinoma.
• Supporting Evidence: MET pathway dysregulation is implicated in kidney cancer, and MET inhibitors are a cornerstone of therapy. GeneCards: MET, PubMed: MET inhibitors renal cell carcinoma

CD47 (CD47 Molecule)

• Signaling Pathways/Mechanisms: CD47 is a "don't eat me" signal. It interacts with SIRPα on phagocytic cells (e.g., macrophages), delivering an inhibitory signal that prevents phagocytosis. Overexpression of CD47 in cancer cells allows them to evade immune surveillance and destruction by macrophages.
• Relevant Therapeutic Agents: Anti-CD47 monoclonal antibodies (e.g., Magrolimab) are in clinical development to block the CD47-SIRPα interaction and promote tumor cell phagocytosis.
• Supporting Evidence: CD47 is a promising immunotherapeutic target in various malignancies, including kidney cancer. GeneCards: CD47, PubMed: CD47 immunotherapy kidney cancer

IL6R (Interleukin 6 Receptor)

• Signaling Pathways/Mechanisms: IL6R is the receptor for Interleukin-6 (IL-6), a pleiotropic cytokine. IL-6/IL6R signaling activates the JAK/STAT3 pathway, promoting inflammation, proliferation, survival, and immune evasion in the tumor microenvironment. It's associated with poor prognosis in several cancers.
• Relevant Therapeutic Agents: Monoclonal antibodies targeting IL-6 or IL6R (e.g., Tocilizumab) are used in inflammatory diseases and explored in oncology to inhibit pro-tumorigenic inflammation and signaling.
• Supporting Evidence: Elevated IL-6 signaling is frequently observed in kidney cancer and contributes to its progression and resistance to therapy. GeneCards: IL6R, PubMed: IL6R renal cell carcinoma

Less Well-Characterized Markers with Potential as Therapeutic Targets

• HLA-DRA (Major Histocompatibility Complex, Class II, DR Alpha) (and other MHC Class II genes like HLA-DRB1, -DPA1, -DPB1, -DQB1, -DMA, -DRB5):
  • Signaling Pathways/Mechanisms: MHC class II molecules are typically expressed on professional antigen-presenting cells (APCs) and present exogenous antigens to CD4+ T cells, initiating adaptive immune responses. Aberrant expression on tumor cells (as seen here on Renal Epithelial cells) can be induced by inflammatory cytokines (e.g., IFN-γ) and might indicate immune evasion mechanisms by modulating immune responses, or potentially present tumor antigens to CD4+ T cells. Its role on tumor cells is complex and context-dependent.
  • Relevant Therapeutic Agents: Not direct targets in themselves, but their expression pattern could inform immunotherapeutic strategies or patient stratification. Modulating the tumor microenvironment to optimize antigen presentation could be a strategy.
  • Supporting Evidence: While MHC class I downregulation is common in cancer, MHC class II expression on tumor cells is less understood but increasingly recognized as a factor influencing anti-tumor immunity. GeneCards: HLA-DRA, PubMed: tumor MHC class II expression

CA12 (Carbonic Anhydrase XII)

• Signaling Pathways/Mechanisms: CA12 is a transmembrane carbonic anhydrase involved in pH regulation. In the hypoxic and acidic tumor microenvironment, CA12 helps cancer cells maintain intracellular pH homeostasis, facilitating their survival, proliferation, and invasion.
• Relevant Therapeutic Agents: Carbonic anhydrase inhibitors (CAIs) are being investigated, some of which are already used as diuretics or anti-glaucoma drugs. Their repurposing or development of novel, specific CA12 inhibitors could be relevant.
• Supporting Evidence: CA12 expression is often elevated in renal cell carcinoma, especially clear cell RCC, due to hypoxia-inducible factor (HIF) activation, making it a potential therapeutic target. GeneCards: CA12, PubMed: CA12 renal cell carcinoma

BST2 (Bone Marrow Stromal Antigen 2, also known as CD317 or tetherin)

• Signaling Pathways/Mechanisms: BST2 is an interferon-inducible transmembrane protein involved in innate immunity, particularly in restricting enveloped virus release. In cancer, BST2 is often overexpressed and can promote tumor cell proliferation, survival, and migration, sometimes by activating pathways like NF-κB. It may also play a role in immune evasion.
• Relevant Therapeutic Agents: Direct inhibitors are not widely available, but understanding its role could lead to novel therapeutic strategies, possibly by targeting its downstream signaling or identifying antibodies.
• Supporting Evidence: BST2 has been identified as a prognostic marker and potential therapeutic target in several cancers, including kidney cancer. GeneCards: BST2, PubMed: BST2 cancer

• TNFRSF14 (Tumor Necrosis Factor Receptor Superfamily Member 14, also known as HVEM):
  • Signaling Pathways/Mechanisms: TNFRSF14 is a receptor for various ligands including LIGHT, BTLA, and CD160. It plays a dual role in immunity and cancer, capable of both co-stimulatory and co-inhibitory signaling, influencing T cell activation and survival. Its expression on tumor cells can modulate immune responses in the tumor microenvironment.
  • Relevant Therapeutic Agents: Targeting this pathway with agonists or antagonists of its ligands could be explored for immunotherapy.
  • Supporting Evidence: Dysregulation of TNFRSF14 and its ligands is implicated in cancer immunity and progression, representing a complex but potentially targetable axis. GeneCards: TNFRSF14, PubMed: TNFRSF14 cancer

SLC2A1 (Solute Carrier Family 2 Member 1, also known as GLUT1)

• Signaling Pathways/Mechanisms: SLC2A1 is a glucose transporter responsible for basal glucose uptake. Its overexpression in cancer cells reflects the "Warburg effect," where cancer cells rely heavily on aerobic glycolysis for energy, even in the presence of oxygen. This metabolic reprogramming supports rapid proliferation.
• Relevant Therapeutic Agents: Glucose transporter inhibitors are under investigation to starve cancer cells of their primary energy source.
• Supporting Evidence: GLUT1 is a classic marker of cancer metabolism and a potential metabolic target. GeneCards: SLC2A1, PubMed: GLUT1 renal cell carcinoma

Clinical or Translational Implications

The identification of these condition-specific surfaceome markers in Renal Epithelial cells has significant clinical and translational implications for Kidney Cancer:

1. Diagnostic and Prognostic Biomarkers: Markers like EPCAM and DPEP1 can serve as indicators of normal renal epithelial identity. Conversely, the high expression of tumor-specific markers such as EGFR, MET, CD47, CA12, BST2, and SLC2A1 could be exploited for early detection, monitoring disease progression, or predicting patient outcomes in kidney cancer, especially in liquid biopsies or imaging.
2. Targeted Therapy Development: The tumor-enriched expression of established therapeutic targets (EGFR, MET, CD47, IL6R) confirms their relevance in kidney cancer and supports the use of existing targeted therapies or the development of new ones. The dataset provides evidence for their specific upregulation in the tumor context, validating their potential for focused intervention.
3. Novel Therapeutic Avenues: Less characterized but highly expressed markers in tumor cells, such as CA12, BST2, TNFRSF14, and various SLC family members (e.g., SLC2A1), represent promising avenues for drug discovery. For example, targeting CA12 could disrupt tumor pH regulation, while inhibiting SLC2A1 could starve highly glycolytic tumor cells. The aberrant expression of MHC class II molecules (HLA-DRA and others) on renal epithelial tumor cells warrants further investigation into its role in immune evasion or presentation, potentially leading to novel immunotherapeutic strategies.
4. Patient Stratification: The variability in marker expression across different tumor samples (SI_XXXXX) suggests that not all tumors may respond uniformly to a given targeted therapy. This highlights the importance of patient stratification based on biomarker expression to tailor treatments, ensuring that therapies are directed to patients most likely to benefit.

In conclusion, this analysis provides a valuable resource for prioritizing surfaceome markers for further investigation as diagnostic tools or therapeutic targets in Kidney Cancer, leveraging both established knowledge and novel findings from single-cell resolution data.

15. Macrophage Condition-Specific Surfaceome Markers in Kidney Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes surfaceome markers differentially expressed in macrophages isolated from 'normal' kidney tissue versus 'tumor' kidney tissue within the context of Kidney Cancer. The objective is to highlight condition-specific surface markers that could serve as indicators of macrophage state, potential therapeutic targets, or biomarkers within the tumor microenvironment (TME). The dot plot displays mean expression levels and the fraction of cells expressing each marker across various samples grouped by 'normal' and 'tumor' conditions.

Visual Summary

The dot plot, titled "Macrophage condition-specific markers," effectively illustrates distinct surfaceome marker profiles between macrophages from normal and tumor kidney tissues.

• Normal-Enriched Markers: A clear cluster of markers (highlighted by the upper red box) shows higher mean expression (darker red color) and a larger fraction of expressing cells (larger dot size) in the 'normal' samples (SI_22605, SI_21255, SI_18856, SI_22369). These include AREG, EREG, CD55, CD52, and FCGR3A. While some of these show very low or no expression in 'tumor' samples, others like CD9 show variable expression.
• Tumor-Enriched Markers: A much larger and more prominent cluster of markers (highlighted by the lower red box) exhibits high expression and prevalence specifically in 'tumor' samples (SI_18854, SI_19703, SI_18855, SI_21561, SI_22604, SI_23459, SI_23843, SI_22368). These markers are largely absent or expressed at very low levels in 'normal' samples. Notable genes in this extensive list include HLA-DMB, CD14, TMEM219, LAIR1, LMAN1, CSF1R, TREM2, CD59, MSR1, GPNMB, AXL, CD4, FOLR2, SIGLEC10, and many others. This indicates a profound shift in macrophage phenotype within the tumor microenvironment.
• Expression and Prevalence: The color intensity (red scale) indicates the mean expression level, with darker reds signifying higher expression. The size of the dot represents the percentage of cells within that group expressing the marker, with larger dots indicating a higher fraction of expressing cells. The majority of tumor-enriched markers show both high mean expression and a high fraction of expressing cells in tumor samples, underscoring their significance.

Biological Interpretation

Macrophages play a critical and often dual role in the tumor microenvironment (TME) of kidney cancer. While some macrophage subsets can exhibit anti-tumor functions (M1-like), tumor-associated macrophages (TAMs) are frequently polarized towards a pro-tumorigenic phenotype (M2-like), promoting tumor growth, angiogenesis, metastasis, and immunosuppression. The identified condition-specific surface markers provide insights into these distinct macrophage states.

Markers Enriched in Normal Macrophages

These markers are generally associated with homeostatic or anti-inflammatory macrophage functions, less pronounced in the tumor context.

AREG (Amphiregulin) and EREG (Epiregulin):

• Signaling Pathways: Both are ligands for the Epidermal Growth Factor Receptor (EGFR) signaling pathway. EGFR activation can promote cell proliferation, survival, and differentiation.
• Role in TME: In normal tissue, AREG and EREG contribute to tissue repair and homeostasis. In cancer, they can sometimes be pro-tumorigenic if expressed by tumor cells, but macrophage-derived AREG/EREG might reflect tissue repair functions or a less immunosuppressive state in normal kidney macrophages.
• Therapeutic Potential: While EGFR is a well-established target, macrophage-specific AREG/EREG expression in normal tissue suggests their role in maintaining tissue integrity. Targeting these specifically on macrophages in a tumor context would require careful consideration of their expression patterns on tumor cells and other stromal cells.

References:

• AREG: https://www.genecards.org/cgi-bin/carddisp.pl?gene=AREG
• EREG: https://www.genecards.org/cgi-bin/carddisp.pl?gene=EREG

CD55 (DAF - Decay-Accelerating Factor):

• Signaling Pathways: CD55 is a glycosylphosphatidylinositol (GPI)-anchored protein that regulates the complement system, preventing the formation of C3 and C5 convertases.
• Role in TME: Macrophage CD55 helps protect host cells from complement-mediated damage, maintaining immune homeostasis. In the context of cancer, upregulation can sometimes protect tumor cells from immune attack. Its enrichment in normal macrophages suggests its role in maintaining normal tissue integrity.
• Therapeutic Potential: CD55 has been explored as a potential target in some cancers to enhance complement-dependent cytotoxicity, but its role in normal macrophages suggests caution.
• References: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD55

CD52:

• Signaling Pathways: CD52 is a GPI-anchored protein expressed on lymphocytes and myeloid cells. Its precise signaling is not fully elucidated, but it can modulate immune responses.
• Role in TME: Macrophage CD52 expression is common. The monoclonal antibody Alemtuzumab targets CD52, leading to immune cell depletion. Its presence in normal macrophages is consistent with its broad immune cell expression.
• Therapeutic Potential: CD52 itself is not typically a direct therapeutic target for modulating macrophage function but rather a target for depleting CD52-expressing cells.
• Relevant Therapeutic Agents: Alemtuzumab.
• References: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD52

Markers Enriched in Tumor-Associated Macrophages (TAMs)

The strong and prevalent expression of numerous surface markers in macrophages from tumor tissue suggests a distinct pro-tumorigenic or immunosuppressive phenotype, characteristic of TAMs in kidney cancer.

CD14:

• Signaling Pathways: A co-receptor for Toll-like receptor 4 (TLR4), involved in the innate immune response to bacterial lipopolysaccharide (LPS).
• Role in TME: While a general macrophage marker, high CD14 expression can be associated with monocyte-macrophage differentiation, activation, and recruitment to the TME, often linked to an M2-like phenotype in cancer.
• Therapeutic Potential: Targeting CD14 directly in the TME might modulate TAM activation, but its broad expression on myeloid cells needs careful consideration.
• References: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD14

CSF1R (Colony Stimulating Factor 1 Receptor / CD115):

• Signaling Pathways: Binds to CSF1 and IL-34, activating downstream pathways like PI3K/Akt, MAPK, and STAT, critical for macrophage proliferation, differentiation, survival, and polarization.
• Role in TME: CSF1/CSF1R signaling is a central axis for TAM recruitment, survival, and pro-tumorigenic polarization (M2-like). High CSF1R expression is a hallmark of TAMs and is often correlated with poor prognosis in various cancers, including kidney cancer.
• Therapeutic Potential: High therapeutic potential. Inhibiting CSF1R can deplete TAMs or reprogram them towards an anti-tumorigenic phenotype, making it a promising strategy in immuno-oncology.
• Relevant Therapeutic Agents: Small molecule inhibitors (e.g., PLX3397/Pexidartinib, Cabiralizumab) and antibodies targeting CSF1R are in clinical trials for various solid tumors.
• References: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CSF1R

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2):

• Signaling Pathways: Forms a signaling complex with DAP12, leading to activation of tyrosine kinases and downstream pathways like PI3K/Akt, involved in phagocytosis, cell survival, and immunomodulation.
• Role in TME: TREM2 is expressed on specific subsets of macrophages, including TAMs, and is implicated in lipid metabolism, debris clearance, and immunosuppression. In cancer, TREM2+ TAMs can promote tumor growth and metastasis.
• Therapeutic Potential: Emerging as an attractive target to modulate TAM functions, potentially reprogramming them to a less immunosuppressive state. Antibodies targeting TREM2 are under investigation.
• References: https://www.genecards.org/cgi-bin/carddisp.pl?gene=TREM2

MSR1 (Macrophage Scavenger Receptor 1 / CD204):

• Signaling Pathways: Involved in phagocytosis of modified lipids and cellular debris. Its signaling pathways are diverse and contribute to macrophage activation states.
• Role in TME: MSR1 is often associated with M2-polarized macrophages. In the TME, it contributes to the immune-suppressive and pro-tumorigenic functions of TAMs, including clearance of apoptotic tumor cells and promotion of angiogenesis.
• Therapeutic Potential: Modulating MSR1 activity could impact the pro-tumorigenic functions of TAMs.
• References: https://www.genecards.org/cgi-bin/carddisp.pl?gene=MSR1

GPNMB (Glycoprotein NMB / Osteoactivin):

• Signaling Pathways: Involved in cell adhesion, migration, and growth. Its intracellular domain can be cleaved and enter the nucleus, affecting gene expression.
• Role in TME: GPNMB is often expressed on TAMs and is associated with tumor progression, invasion, and metastasis in various cancers, including melanoma and breast cancer. It can promote an immunosuppressive environment.
• Therapeutic Potential: Considered a promising therapeutic target due to its restricted expression in normal tissues and high expression in aggressive tumors and TAMs. Antibody-drug conjugates (ADCs) targeting GPNMB are under development.
• Relevant Therapeutic Agents: Glembatumumab vedotin (ADC targeting GPNMB).
• References: https://www.genecards.org/cgi-bin/carddisp.pl?gene=GPNMB

AXL (AXL Receptor Tyrosine Kinase):

• Signaling Pathways: Receptor for growth arrest-specific protein 6 (GAS6), activating PI3K/Akt, MAPK, and NF-κB pathways. Involved in cell proliferation, survival, migration, and immune regulation.
• Role in TME: AXL is frequently overexpressed in TAMs and contributes to their pro-tumorigenic functions, including promoting immunosuppression, angiogenesis, and resistance to therapy. It is also expressed on tumor cells.
• Therapeutic Potential: High therapeutic potential due to its widespread role in tumor progression and immune evasion. AXL inhibitors are in clinical development.
• Relevant Therapeutic Agents: Bemcentinib (AXL inhibitor) is being investigated in clinical trials.
• References: https://www.genecards.org/cgi-bin/carddisp.pl?gene=AXL

FOLR2 (Folate Receptor Beta):

• Signaling Pathways: Involved in the cellular uptake of folates, essential for DNA synthesis and repair.
• Role in TME: FOLR2 is often expressed on activated macrophages, particularly M2-like TAMs, and is associated with inflammation and immunosuppression. It can be exploited for targeted drug delivery to TAMs.
• Therapeutic Potential: Represents a promising target for delivering cytotoxic agents or imaging probes specifically to TAMs, sparing other cells.
• References: https://www.genecards.org/cgi-bin/carddisp.pl?gene=FOLR2

SIGLEC10 (Sialic Acid Binding Ig Like Lectin 10):

• Signaling Pathways: A member of the Siglec family of inhibitory receptors that bind to sialic acid-containing glycans. Upon ligand binding, it recruits phosphatases (e.g., SHP-1, SHP-2), leading to inhibition of cellular activation.
• Role in TME: Functions as an immune checkpoint, promoting immune evasion by suppressing anti-tumor immune responses, particularly from T cells and NK cells, in the TME. Tumor cells can express sialylated ligands that engage SIGLEC10 on TAMs.
• Therapeutic Potential: Emerging as a novel immune checkpoint target. Blocking SIGLEC10 can potentially unleash anti-tumor immunity by enhancing macrophage and T cell effector functions.
• References: https://www.genecards.org/cgi-bin/carddisp.pl?gene=SIGLEC10

HLA-DMB, HLA-F, HLA-DOA (MHC Class II related genes):

• Signaling Pathways: Involved in antigen presentation. HLA-DMB and HLA-DOA are non-classical MHC class II molecules involved in peptide loading. HLA-F is a non-classical MHC class I molecule.
• Role in TME: While MHC class II molecules are critical for presenting antigens to T helper cells, their aberrant expression or regulation on TAMs can contribute to altered antigen presentation or immune evasion, consistent with an immunosuppressive TAM phenotype.
• Therapeutic Potential: Modulating antigen presentation machinery on TAMs is complex, but understanding these molecules' roles in TAMs can inform strategies to enhance anti-tumor immunity.

References:

• HLA-DMB: https://www.genecards.org/cgi-bin/carddisp.pl?gene=HLA-DMB
• HLA-F: https://www.genecards.org/cgi-bin/carddisp.pl?gene=HLA-F

IL10RB (Interleukin 10 Receptor Subunit Beta):

• Signaling Pathways: A component of the receptor complex for IL-10, an immunosuppressive cytokine. IL-10 signaling activates the JAK/STAT pathway, primarily STAT3, leading to gene expression changes that suppress inflammatory responses.
• Role in TME: Upregulation of IL10RB on TAMs suggests increased responsiveness to IL-10, thereby reinforcing their immunosuppressive functions and contributing to immune tolerance in the TME.
• Therapeutic Potential: Targeting the IL-10/IL10RB axis could potentially reverse TAM-mediated immunosuppression, though this pathway is complex due to IL-10's diverse roles.
• References: https://www.genecards.org/cgi-bin/carddisp.pl?gene=IL10RB

Clinical or Translational Implications

The distinct surfaceome profiles of macrophages in normal versus tumor kidney tissue offer significant clinical and translational implications for Kidney Cancer:

1. Biomarker Discovery: The identified tumor-enriched markers (e.g., CSF1R, TREM2, GPNMB, AXL, FOLR2, SIGLEC10) could serve as highly specific biomarkers for identifying and characterizing pro-tumorigenic TAMs in kidney cancer. These could be investigated for diagnostic or prognostic utility, for example, via immunohistochemistry on tissue biopsies or by flow cytometry of infiltrating immune cells.
2. Therapeutic Target Identification: Several highly expressed tumor-associated macrophage markers represent promising therapeutic targets for modulating the immunosuppressive TME in kidney cancer:
   • CSF1R: Inhibitors are already in clinical trials. Targeting CSF1R aims to deplete TAMs or reprogram them to an anti-tumorigenic state, potentially enhancing the efficacy of other immunotherapies.
   • AXL: Inhibitors are being developed and could be effective against AXL-expressing TAMs and tumor cells, addressing multiple facets of tumor progression and drug resistance.
   • GPNMB: Antibody-drug conjugates (ADCs) targeting GPNMB offer a strategy for selective delivery of cytotoxic agents to GPNMB+ TAMs and tumor cells, potentially reducing systemic toxicity.
   • FOLR2: Its expression on TAMs could be leveraged for targeted drug delivery strategies, allowing for precise delivery of therapeutic payloads directly to these pro-tumorigenic cells.
   • SIGLEC10: As an immune checkpoint, blocking SIGLEC10 could unleash anti-tumor immune responses, similar to current PD-1/PD-L1 therapies, but specifically targeting a myeloid inhibitory pathway.
3. Combination Therapies: Targeting TAMs (e.g., via CSF1R, AXL, or SIGLEC10 inhibition) could synergize with existing immunotherapies (e.g., PD-1/PD-L1 inhibitors) or conventional treatments to overcome resistance mechanisms and improve patient outcomes in kidney cancer.
4. Understanding Macrophage Plasticity: The data highlights the dynamic nature of macrophage populations in cancer. Understanding the signaling pathways associated with these differentially expressed markers can provide insights into the mechanisms driving TAM polarization and help design strategies to re-educate these cells into an anti-tumorigenic state.

Further validation of these markers in larger patient cohorts and functional studies are warranted to fully elucidate their roles and clinical applicability in kidney cancer.

16. Condition-Specific Surfaceome Markers in Kidney CD4+ T Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies surfaceome markers differentially expressed in CD4+ T cells between normal and tumor conditions in kidney tissue. The dot plot displays the mean expression level and the fraction of cells expressing each marker for three identified groups of CD4+ T cells (SI_22369, SI_23459, SI_22368) across normal and tumor microenvironments. The selection criteria for markers were based on non-zero percentage score (nz_pct_score) and fold change (nz_pct_FC) thresholds, prioritizing surfaceome genes. This provides insights into the phenotypic heterogeneity and functional states of CD4+ T cells in the context of kidney cancer.

Visual Summary

The dot plot effectively visualizes condition-specific marker expression for CD4+ T cells.

• Group SI_22369 (165 cells): This group is predominantly characterized by markers highly expressed in the normal condition. Notably, *PTPRC*, *AREG*, and *CD52* show high mean expression (dark red color) and are expressed in a large fraction of cells (large dot size) within the normal samples. These markers are significantly downregulated or absent in the tumor condition for this group.
• Group SI_23459 (35 cells): This group displays a strong signature of markers highly expressed in the tumor condition. A broad panel of markers, including *HLA-E*, *CD3D*, *IL7R*, *KLRB1*, *ITM2B*, *CD44*, *CD37*, *CD7*, *CD48*, *EMP3*, *GYPC*, *CD53*, *LY6E*, *HLA-DRA*, *S1PR4*, *HLA-DPB1*, *HLA-DRB1*, *ICAM3*, and *CD63*, show high mean expression and are present in a substantial fraction of cells within the tumor compartment. These markers are largely absent or very lowly expressed in the normal samples for this group.
• Group SI_22368 (606 cells): This is the largest group and also shows markers enriched in the tumor condition, largely overlapping with those identified in SI_23459. However, for many markers, the mean expression (color intensity) appears lower compared to SI_23459 (e.g., *CD3D*, *IL7R*, *HLA-DRA*, *HLA-DPB1*, *HLA-DRB1*). This suggests potential heterogeneity in activation or functional states among tumor-infiltrating CD4+ T cells.

In summary, the analysis identifies distinct subsets of CD4+ T cells with specific surface marker profiles associated with either normal kidney tissue or the tumor microenvironment.

Biological Interpretation

CD4+ T cells are crucial orchestrators of adaptive immunity and play diverse roles in the tumor microenvironment (TME) of kidney cancer, ranging from anti-tumor immunity (e.g., Th1 cells) to immunosuppression (e.g., regulatory T cells, Tregs). The observed condition-specific markers shed light on potential functional shifts in these cells.

Markers Enriched in Normal CD4+ T Cells (Group SI_22369)

PTPRC (CD45):

• Signaling Pathways: PTPRC is a receptor-like protein tyrosine phosphatase that plays a critical role in regulating T-cell antigen receptor (TCR) signaling thresholds. It is involved in both activating and inhibitory signals, modulating the phosphorylation of Src family kinases (e.g., Lck, Fyn) and other signaling molecules essential for T cell activation. GeneCards: PTPRC
• Role in TME: As a pan-leukocyte marker, CD45 is broadly expressed on immune cells. Its presence here is consistent with healthy, circulating, or tissue-resident CD4+ T cells. Lower expression in tumor-associated T cells or different isoforms can sometimes be associated with altered activation states or exhaustion, but its strong expression in normal cells here indicates a healthy immune population.
• Therapeutic Target Potential: CD45 itself is generally not a direct therapeutic target for modulating T cell function in cancer due to its ubiquitous expression on immune cells. However, its isoforms (CD45RA, CD45RO) are used to distinguish naive vs. memory T cells, which can have therapeutic implications.
• Therapeutic Agents: N/A (not a direct therapeutic target in this context).

AREG (Amphiregulin):

• Signaling Pathways: AREG is a member of the epidermal growth factor (EGF) family and functions as a ligand for the epidermal growth factor receptor (EGFR). It activates the EGFR/MAPK/PI3K-Akt signaling pathways, promoting cell proliferation, survival, and migration. GeneCards: AREG
• Role in TME: While often associated with stromal or cancer cells, AREG can be produced by immune cells, including T cells. Its enrichment in normal CD4+ T cells could suggest a role in tissue homeostasis or early immune responses, potentially distinct from tumor-promoting roles observed in other cell types within the TME. High AREG in normal T cells might reflect a baseline function that is altered in the tumor environment.
• Therapeutic Target Potential: EGFR is a major target in oncology. While AREG is a ligand, targeting AREG directly could modulate EGFR signaling, especially where AREG is a key driver.
• Therapeutic Agents: EGFR inhibitors (e.g., cetuximab, panitumumab) are widely used in cancer, but these target the receptor, not specifically AREG from T cells. Direct AREG inhibitors are less common in clinical use.

CD52:

• Signaling Pathways: CD52 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein of unknown function, but its broad expression on immune cells makes it a target for depletion. It is thought to be involved in cell adhesion and costimulation. GeneCards: CD52
• Role in TME: Its presence on normal CD4+ T cells reflects its general expression on lymphocytes and other immune cells. The decrease in tumor cells (comparing SI_22369 normal vs. SI_23459 tumor) might suggest altered surface protein profiles in the tumor microenvironment or a shift in CD4+ T cell subsets.
• Therapeutic Target Potential: CD52 is an established therapeutic target for lymphocyte depletion, particularly in autoimmune diseases and certain hematologic malignancies.
• Therapeutic Agents: Alemtuzumab (anti-CD52 antibody) is used for conditions like chronic lymphocytic leukemia (CLL) and multiple sclerosis, acting by depleting CD52-expressing lymphocytes.

Markers Enriched in Tumor-Associated CD4+ T Cells (Groups SI_23459 and SI_22368)

CD3D (part of CD3 complex):

• Signaling Pathways: CD3D is a critical component of the T-cell receptor (TCR) complex, which initiates intracellular signaling upon antigen recognition. It couples antigen binding to downstream signaling cascades involving Src family kinases (Lck, Fyn), ZAP-70, and adaptor proteins, leading to T cell activation, proliferation, and effector functions. GeneCards: CD3D
• Role in TME: High expression of CD3D on tumor-infiltrating CD4+ T cells indicates the presence of functional T cells, capable of recognizing antigens. This is essential for both anti-tumor (e.g., Th1) and pro-tumor (e.g., Treg) responses.
• Therapeutic Target Potential: The TCR/CD3 complex is central to T cell function. While not a direct target for *depletion* in cancer due to its necessity for anti-tumor immunity, modulating TCR signaling (e.g., with CAR T cells or bispecific antibodies that engage CD3) is a core strategy in immunotherapy.
• Therapeutic Agents: Bispecific T-cell engagers (BiTEs) like blinatumomab (targets CD19 and CD3) redirect T cells to cancer cells. CD3 is also a component of chimeric antigen receptor (CAR) T cell design.

CD44:

• Signaling Pathways: CD44 is a transmembrane glycoprotein that acts as a receptor for hyaluronic acid (HA) and other ligands. It mediates cell-cell and cell-matrix interactions, playing roles in cell adhesion, migration, proliferation, and survival. It can interact with various intracellular signaling molecules, including ERM proteins and Src kinases. GeneCards: CD44
• Role in TME: CD44 is often associated with activated, memory, or regulatory T cells. In the TME, it facilitates lymphocyte extravasation, migration, and retention. Upregulation can indicate T cell activation, homing to inflammatory sites, or adaptation to the TME. CD44v6 isoform can contribute to T cell stemness and persistence.
• Therapeutic Target Potential: CD44's role in cell adhesion and migration makes it a potential target to modulate immune cell trafficking or directly target certain cancer stem cells.
• Therapeutic Agents: Antibodies targeting CD44 are under investigation for their potential to inhibit tumor progression or modulate immune responses.

HLA-DRA, HLA-DPB1, HLA-DRB1 (MHC Class II molecules):

• Signaling Pathways: These genes encode components of MHC Class II proteins, which are crucial for presenting extracellular antigens to CD4+ T helper cells. They initiate TCR signaling upon binding to the TCR on CD4+ T cells, leading to T cell activation and differentiation. GeneCards: HLA-DRA, GeneCards: HLA-DPB1, GeneCards: HLA-DRB1
• Role in TME: While typically expressed on professional antigen-presenting cells (APCs), CD4+ T cells can upregulate MHC Class II molecules upon activation, particularly in inflammatory environments. This suggests activated T cells that might be involved in cell-cell communication, potentially even acting as APCs in certain contexts within the tumor, or are responding to local inflammation. Their expression often correlates with T cell activation status.
• Therapeutic Target Potential: Modulating MHC Class II expression or function on T cells is not a direct therapeutic strategy for cancer, but it informs on the activation state and potential for antigen recognition within the TME.
• Therapeutic Agents: N/A for direct targeting of these on T cells in cancer.

IL7R (CD127):

• Signaling Pathways: IL7R is the receptor for Interleukin-7 (IL-7). IL-7/IL7R signaling is critical for T cell development, survival, and proliferation, especially memory T cells. It activates the JAK/STAT pathway (JAK1/3, STAT5), PI3K/Akt, and MAPK pathways, promoting lymphocyte survival. GeneCards: IL7R
• Role in TME: CD127 expression can distinguish different CD4+ T cell subsets. For example, Tregs often suppress CD127 expression. Its high expression in tumor-associated CD4+ T cells could indicate active T cell populations (e.g., Th1, Th17, memory T cells) that are trying to survive and proliferate in the TME. A lack of CD127 can indicate T cell exhaustion.
• Therapeutic Target Potential: Modulating IL-7/IL7R signaling could influence T cell survival and expansion. Agonists could boost anti-tumor T cell responses, while antagonists might inhibit pro-tumor subsets.
• Therapeutic Agents: IL-7 mimetics or recombinant IL-7 are being explored in clinical trials to enhance T cell numbers and function, particularly for adoptive cell therapies.

KLRB1 (CD161):

• Signaling Pathways: KLRB1 is a C-type lectin receptor expressed on NK cells and certain T cell subsets. It acts as an inhibitory receptor, regulating immune cell activation by interacting with its ligand, lectin-like transcript 1 (LLT1). It can modulate TCR signaling and cytokine production. GeneCards: KLRB1
• Role in TME: CD161 is highly expressed on mucosa-associated invariant T (MAIT) cells and Th17 cells, as well as some NK cells. Its presence on tumor-infiltrating CD4+ T cells might indicate an enrichment of specific functional subsets, such as MAIT cells (which can have anti-tumor properties) or Th17 cells, whose role in RCC is context-dependent (can be pro- or anti-tumor).
• Therapeutic Target Potential: Modulating CD161 activity could impact the function of specific immune cell subsets in the TME. Targeting its inhibitory function might enhance anti-tumor immunity.
• Therapeutic Agents: Research is ongoing into antibodies targeting CD161 or its ligand to influence anti-tumor immunity.

S1PR4 (Sphingosine-1-phosphate receptor 4):

• Signaling Pathways: S1PR4 is a G protein-coupled receptor for sphingosine-1-phosphate (S1P), a bioactive lipid. S1P-S1PR signaling is critical for lymphocyte egress from lymphoid organs and trafficking, as well as cell survival, proliferation, and migration. S1PR4 is often coupled to Gi/o proteins. GeneCards: S1PR4
• Role in TME: Upregulation of S1PR4 in tumor-infiltrating CD4+ T cells could be involved in their recruitment to, or retention within, the TME. It may also influence their survival and effector functions. Different S1PRs have distinct roles in lymphocyte trafficking; S1PR4 is expressed on various immune cells and its role in cancer is still being elucidated.
• Therapeutic Target Potential: Targeting S1PRs, particularly S1PR1, is a strategy for modulating immune cell trafficking in autoimmune diseases. S1PR4-specific modulation could be explored for fine-tuning immune responses in cancer, though its precise role in anti-tumor immunity is complex.
• Therapeutic Agents: FTY720 (fingolimod), an S1PR modulator, is used in multiple sclerosis to sequester lymphocytes in lymph nodes. More selective S1PR4 modulators are under investigation for various conditions.

Clinical or Translational Implications

The identification of condition-specific surface markers on CD4+ T cells in kidney cancer has several potential clinical and translational implications:

1. Biomarker Discovery: The differentially expressed markers (e.g., *AREG*, *CD52* in normal, and *CD44*, *IL7R*, *KLRB1*, *MHC Class II molecules* in tumor) could serve as biomarkers to distinguish between healthy and tumor-associated CD4+ T cell populations. This could aid in diagnosis, prognosis, or monitoring treatment responses in kidney cancer.
2. Therapeutic Targeting:
   • Depletion Strategies: Markers like *CD52* (though highly expressed in normal T cells in this specific subpopulation) are established targets for immune cell depletion. If a specific pro-tumorigenic CD4+ T cell subset in the tumor uniquely expresses a certain marker, it could be targeted for depletion without broadly affecting beneficial immune cells.
   • Immune Modulation: Markers involved in T cell activation, migration, and survival (*CD3D*, *CD44*, *IL7R*, *S1PR4*) represent potential targets for modulating anti-tumor immune responses. For instance, enhancing IL-7/IL7R signaling might boost anti-tumor T cell function, while inhibiting CD44 could impact T cell infiltration or retention in the TME.
   • CAR T cell and BiTE therapy: While CD3D is not a direct target for *inhibiting* T cells, its ubiquitous presence on T cells makes it a critical component for redirecting T cells via bispecific antibodies (BiTEs) or chimeric antigen receptor (CAR) T cells to recognize and kill cancer cells.
3. Phenotypic Characterization of TME: The distinct profiles of SI_23459 and SI_22368 within the tumor microenvironment suggest phenotypic heterogeneity within tumor-infiltrating CD4+ T cells. Further studies could elucidate whether these represent different functional subsets (e.g., effector T cells, exhausted T cells, Tregs) and their relative contributions to tumor progression or control in kidney cancer. Understanding this heterogeneity is crucial for developing targeted immunotherapies.
4. Prognostic Value: The presence and specific expression patterns of these markers in tumor-infiltrating CD4+ T cells could correlate with patient outcomes or response to existing immunotherapies (e.g., checkpoint inhibitors). For instance, high expression of MHC Class II molecules on activated CD4+ T cells might indicate a more immune-responsive TME.

17. Dysregulated Cell Cycle Gene Expression in Renal Epithelial Cells from Kidney Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the "expressing cell fraction (sample)" of a predefined set of cell cycle pathway genes within Renal Epithelial cells, comparing 'tumor' and 'normal' conditions. The "expressing cell fraction" represents the proportion of cells within each sample that exhibit detectable expression of a given gene. This provides insight into the prevalence of cells actively engaged in or regulating cell cycle processes under different conditions. The goal is to identify cell cycle genes with statistically significant expression differences that may contribute to kidney cancer pathogenesis.

Visual Summary

The box plots display the expressing cell fraction for 12 selected cell cycle genes across 'tumor' (blue boxes) and 'normal' (orange boxes) samples of Renal Epithelial cells. Each dot represents a distinct sample.

Several genes show a statistically significant (p < 0.05) or near-significant difference in their expressing cell fraction between tumor and normal conditions:

Significantly Higher in Tumor (p < 0.05):

CCND1 (p=0.0103)

PTTG1 (p=0.0155)

DBF4 (p=0.0217)

CDKN2B (p=0.0282)

CDKN2A (p=0.0315)

CHEK1 (p=0.0477)

These genes consistently show a higher median expressing cell fraction in tumor samples compared to normal samples, with distinct separation between the box plots.

Borderline Significance (p < 0.1):

• CDKN1B (p=0.0606): Higher in tumor.
• CDKN1A (p=0.0606): Higher in tumor.
• MYC (p=0.061): Higher in tumor.
• YWHAG (p=0.0756): Higher in tumor.
• E2F4 (p=0.0882): Higher in tumor.
• TFDP1 (p=0.082): Interestingly, this gene shows a *lower* median expressing cell fraction in tumor samples compared to normal samples, a contrasting pattern to the others.

Overall, the majority of the plotted cell cycle genes exhibit an elevated expressing cell fraction in Renal Epithelial cells derived from tumor tissue, indicating increased cell cycle activity or a shift in the cell cycle regulatory landscape.

Biological Interpretation

The observed upregulation in the expressing cell fraction of numerous cell cycle genes in Renal Epithelial cells from kidney tumors strongly suggests a dysregulation of normal cell proliferation controls, a hallmark of cancer.

1. Increased Proliferative Drive: Genes like CCND1 (Cyclin D1), PTTG1 (Securin), DBF4, MYC, YWHAG, and E2F4 show a higher fraction of expressing cells in the tumor condition.
   • CCND1 is a key G1 cyclin, promoting progression through the G1 phase and into S phase PubMed search: CCND1 cancer proliferation. Its overexpression is a common oncogenic event.
   • PTTG1 (Securin) is crucial for sister chromatid separation during mitosis. Its overexpression can lead to chromosomal instability, a driver of tumor evolution.
   • DBF4 is a regulatory subunit of CDC7 kinase, essential for initiating DNA replication. Increased DBF4 indicates active DNA synthesis.
   • MYC is a potent proto-oncogene that drives cell growth and division, and its dysregulation is central to many cancers.

These findings collectively point to an accelerated and uncontrolled cell cycle progression in tumor-associated Renal Epithelial cells.

2. Cell Cycle Checkpoint Activation/Stress Response: Intriguingly, several cyclin-dependent kinase inhibitors (CDKIs) and checkpoint proteins, such as CDKN2B (p15INK4b), CDKN2A (p16INK4a), CDKN1A (p21), CDKN1B (p27), and CHEK1, also show a higher expressing cell fraction in tumor cells.
   • CDKN2A and CDKN2B are tumor suppressor genes that inhibit CDK4/6, thereby arresting the cell cycle in G1 GeneCards: CDKN2A. Similarly, CDKN1A and CDKN1B inhibit a broader range of CDKs. While their functional inactivation is common in cancer, increased expression in a *fraction* of tumor cells might reflect a cellular stress response (e.g., oncogene-induced stress, DNA damage accumulation) attempting to trigger cell cycle arrest or senescence. This response, however, is often overridden or evaded by the robust proliferative machinery in aggressive tumors.
   • CHEK1 (Checkpoint Kinase 1) is a critical component of DNA damage response pathways, mediating cell cycle arrest to allow for DNA repair UniProt: CHEK1. Its increased expression fraction in tumor cells is consistent with heightened genomic instability and replication stress characteristic of fast-growing cancer cells.
3. Complex Transcriptional Regulation: The contrasting pattern for TFDP1 (DP1), showing a lower expressing cell fraction in tumor cells, is notable. TFDP1 partners with E2F transcription factors to regulate cell cycle-related gene expression. While many E2F-regulated genes are commonly upregulated in cancer, a decrease in TFDP1 might suggest a shift in E2F/DP complex composition or alternative regulatory mechanisms becoming dominant in kidney cancer, possibly involving other DP family members or altered post-translational modifications.

These results, observed specifically in Renal Epithelial cells, align with the inferred context of Kidney Cancer, where uncontrolled proliferation and genomic instability are key features. The differential expression patterns suggest that tumor cells are not only actively proliferating but also potentially experiencing high levels of cellular stress, leading to the activation of checkpoint pathways, albeit possibly ineffectively in restraining overall tumor growth.

Clinical or Translational Implications

The identified cell cycle genes with altered expressing cell fractions in Renal Epithelial cells of kidney tumors could have several clinical implications:

1. Biomarkers of Proliferation: Genes like CCND1, PTTG1, DBF4, and MYC could serve as biomarkers for assessing the proliferative activity of kidney tumors. High expression fractions might correlate with tumor aggressiveness, prognosis, or response to therapy.
2. Therapeutic Targets: The dysregulation of these cell cycle pathways highlights their potential as therapeutic targets. Inhibitors of CDKs (e.g., CDK4/6 inhibitors for CCND1 pathways) or checkpoint kinases (e.g., CHK1 inhibitors) are already being explored or used in cancer therapy. Targeting DBF4 or PTTG1 could also disrupt tumor cell proliferation and survival.
3. Understanding Treatment Resistance: The co-occurrence of increased proliferative markers and checkpoint activators (e.g., CHEK1, CDKNs) in tumor cells might shed light on mechanisms of treatment resistance. Tumors under high replication stress that upregulate CHEK1 might be particularly sensitive to CHK1 inhibitors, or, conversely, might exhibit resistance if other pathways compensate for checkpoint activation.

18. Gene Ontology (GSA) Analysis of Renal Epithelial Cells in Kidney Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GSA) results for Renal Epithelial cells, comparing two conditions: "normal_vs_others" and "tumor_vs_others". The enrichment analysis is based on up-regulated differentially expressed genes (DEGs) in each respective condition. The results highlight key biological processes and pathways that are significantly active in normal renal epithelial cells versus those that are aberrantly upregulated in tumor-derived renal epithelial cells within the kidney tissue.

Visual Summary

The provided bar plots illustrate the top enriched biological terms (pathways/GO terms) in Renal Epithelial cells. The x-axis represents the statistical significance of enrichment, indicated by -log(p-val) and -log(q-val), where higher values denote greater significance.

Panel 1: GSA for Renal Epithelial cells (Normal vs. Others)

This plot shows terms enriched in normal renal epithelial cells when compared to other cell types or conditions. The top enriched terms predominantly reflect core metabolic functions and specialized kidney physiological processes. Highly significant terms include "Oxidative phosphorylation", "Valine, leucine and isoleucine degradation", "Ribosome", "Collecting duct acid secretion", "Proximal tubule bicarbonate reclamation", "Fatty acid degradation", and "Citrate cycle (TCA cycle)". Several neurodegenerative disease pathways also appear, likely reflecting shared fundamental cellular processes like mitochondrial dysfunction or protein aggregation rather than primary kidney pathology.

Panel 2: GSA for Renal Epithelial cells (Tumor vs. Others)

This plot displays terms enriched in renal epithelial cells from the tumor condition when compared to other cell types or conditions. In stark contrast to normal cells, tumor-associated renal epithelial cells show significant upregulation of pathways related to "Protein processing in endoplasmic reticulum", "Spliceosome", "Apoptosis", "NF-kappa B signaling pathway", "TNF signaling pathway", "HIF-1 signaling pathway", and critically, "Pathways in cancer". A substantial number of infection-related pathways also show enrichment, suggesting an altered immune and inflammatory microenvironment.

Biological Interpretation

The GSA results reveal profound biological shifts in Renal Epithelial cells when transitioning from a normal physiological state to a cancerous one in the context of kidney cancer.

Normal Renal Epithelial Cell Function:

• High Metabolic Activity: Normal renal epithelial cells are characterized by robust metabolic activity, particularly high Oxidative phosphorylation and the Citrate cycle (TCA cycle), indicating efficient energy production crucial for their demanding physiological roles. There is also strong enrichment for various amino acid (e.g., valine, leucine, isoleucine, glycine, serine, threonine, arginine, proline, cysteine, methionine, lysine, alanine, aspartate, glutamate) and fatty acid metabolism pathways, underscoring their active role in nutrient processing and energy homeostasis.
• Specialized Kidney Functions: Significantly, terms like "Collecting duct acid secretion" and "Proximal tubule bicarbonate reclamation" are highly enriched. These directly reflect the specialized ion transport and acid-base regulation functions unique to different segments of renal tubules, confirming the identity and functional integrity of these normal kidney cells. "Mineral absorption" also highlights a specific renal function.
• Cellular Infrastructure: The enrichment of "Ribosome" and "Tight junction" pathways indicates active protein synthesis and the maintenance of epithelial barrier integrity.

Tumor Renal Epithelial Cell Pathobiology:

• Oncogenic Signaling and Stress Response: In the tumor context, renal epithelial cells upregulate canonical cancer pathways such as "Pathways in cancer", "HIF-1 signaling pathway", and "PI3K-Akt signaling pathway". This signifies active tumor cell proliferation, survival, and adaptation to the hypoxic tumor microenvironment. The strong enrichment for "Protein processing in endoplasmic reticulum" and "Ubiquitin mediated proteolysis" suggests increased proteotoxic stress due to high protein synthesis demand and potential protein misfolding, a common feature in rapidly dividing cancer cells.
• Altered Immune and Inflammatory Milieu: A striking observation is the significant upregulation of numerous immune and inflammation-related pathways, including "NF-kappa B signaling pathway", "TNF signaling pathway", and "Antigen processing and presentation". The widespread enrichment of various infection-related terms (e.g., Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Salmonella infection, etc.) may indicate a generalized inflammatory response within the tumor microenvironment or a reprogramming of host defense mechanisms, rather than specific infections. This suggests a complex interplay between tumor cells and the immune system.
• Dysregulated Cell Fate: Enrichment of "Apoptosis" and "Necroptosis" pathways indicates that programmed cell death mechanisms are actively modulated or engaged in the tumor context, potentially as a response to cellular stress, DNA damage, or anti-tumor immunity, or even subverted for tumor survival.
• Loss of Kidney-Specific Function: Notably, the kidney-specific functions prominently seen in normal cells (e.g., Collecting duct acid secretion, Proximal tubule bicarbonate reclamation) are absent from the enriched pathways in tumor cells. This reflects a process of dedifferentiation, where cancer cells lose their specialized tissue-specific functions in favor of sustained proliferation and survival, a hallmark of malignancy.
• RNA Processing Alterations: Enrichment of "Spliceosome" and "RNA transport" pathways points towards global alterations in RNA processing and gene expression regulation, which are critical for cancer development and progression.

Clinical or Translational Implications

The distinct pathway enrichments in normal versus tumor renal epithelial cells offer several potential clinical and translational implications for Kidney Cancer:

• Biomarker Identification: The clear differences in metabolic and signaling pathway activity could yield novel diagnostic or prognostic biomarkers. For instance, genes involved in specific kidney functions (upregulated in normal) versus those in HIF-1 or PI3K-Akt signaling (upregulated in tumor) could help distinguish healthy tissue from cancerous lesions.
• Therapeutic Targeting: Pathways such as HIF-1 signaling and PI3K-Akt signaling, which are significantly upregulated in tumor cells, represent established targets for anti-cancer therapies. The observed enrichment supports the rationale for using existing inhibitors or developing new agents against these pathways in kidney cancer. Additionally, targeting the endoplasmic reticulum stress response could be a viable strategy.
• Immunotherapy Context: The pronounced inflammatory and immune-related signatures in tumor cells (NF-kappa B, TNF, antigen processing) suggest that the tumor microenvironment is immunologically active. This provides a strong rationale for investigating or applying immunotherapeutic approaches, such as immune checkpoint inhibitors, in Kidney Cancer, potentially leveraging the observed immune activation patterns.
• Understanding Dedifferentiation: The loss of specialized renal functions in tumor cells highlights a key characteristic of cancer progression. Understanding the mechanisms driving this dedifferentiation could inform strategies to promote re-differentiation, potentially leading to less aggressive tumor phenotypes.

19. Gene Set Enrichment Analysis (GSEA) Across Kidney Tissue Cell Types in Tumor and Normal Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results, visualized as a dot plot, for various kidney cell types comparing tumor and normal conditions. The goal is to identify enriched biological pathways and processes characteristic of specific cell types within the tumor microenvironment (TME) and in healthy tissue. The analysis utilizes precomputed GSEA results, comparing each cell type in a given condition (tumor or normal) against its counterpart in the reference condition ('normal') for upregulated pathways.

Visual Summary

The dot plot displays 120 enriched gene sets (pathways) on the y-axis and different cell type-condition comparisons on the x-axis.

• X-axis: Each comparison is labeled as celltype: condition_vs_others, signifying an enrichment analysis for genes differentially expressed in that specific cell type and condition against the same cell type in the reference 'normal' condition. For example, "Renal Epithelial cell: tumor_vs_others" compares renal epithelial cells from tumor samples against renal epithelial cells from normal samples.
• Dot Color (NES): The color of each dot represents the Normalized Enrichment Score (NES). Red indicates a positive NES, meaning the pathway is significantly upregulated or enriched in the 'test' condition (e.g., tumor) compared to the 'reference' condition (normal). Blue indicates a negative NES, meaning the pathway is downregulated or depleted in the 'test' condition. The RdBu_r colormap is used, where red is positive and blue is negative.
• Dot Size (-log(p-val)): The size of the dot corresponds to the negative logarithm of the adjusted p-value. Larger dots signify higher statistical significance of the enrichment.

Key visual patterns observed:

• There is a clear inverse relationship in NES values between condition: tumor_vs_others and condition: normal_vs_others for the same cell type. If a pathway is highly enriched (red, positive NES) in the tumor condition, it tends to be depleted (blue, negative NES) in the normal condition for the same cell type, and vice versa. This reflects the differential pathway activity between the two states.
• Many pathways related to cell proliferation, metabolism, and immune response are significantly enriched (large red dots) in tumor-associated cell types, particularly the 'Renal Epithelial cell: tumor_vs_others' and various immune and stromal cell populations within the tumor microenvironment.

Biological Interpretation

1. Renal Epithelial Cells (Tumor-Origin):

As the identified tumor-origin cell type, Renal Epithelial cells in the tumor condition ("Renal Epithelial cell: tumor_vs_others") exhibit strong enrichment for pathways indicative of cancer progression:

• Cancer-specific pathways: "Pathways in cancer", "Transcriptional misregulation in cancer", "Proteoglycans in cancer" are highly enriched, reflecting uncontrolled growth and altered cellular functions.
• Proliferation and Survival: "PI3K-Akt signaling pathway", "HIF-1 signaling pathway", "mTOR signaling pathway", "Purine metabolism", "Pyrimidine metabolism", and "Ubiquitin mediated proteolysis" are prominently upregulated. These pathways are crucial for cell growth, metabolism, and evasion of apoptosis in many cancers, including kidney cancer where mutations often lead to HIF-1 pathway activation. PubMed search: HIF-1 kidney cancer metabolism
• Metabolic Reprogramming: "Glycolysis / Gluconeogenesis" is highly enriched, indicating a shift towards Warburg effect-like metabolism common in cancer cells for rapid ATP production and biomass synthesis.
• Cell Adhesion and Structure: Pathways like "Focal adhesion" and "Regulation of actin cytoskeleton" are enriched, which can contribute to cell migration and invasion. Conversely, "Adherens junction" and "Tight junction" pathways are significantly *depleted* (blue dots) in tumor renal epithelial cells, suggesting a loss of epithelial integrity, consistent with epithelial-mesenchymal transition (EMT) and increased invasiveness. PubMed search: EMT kidney cancer invasion

2. Tumor Microenvironment (TME) Components:

• Macrophage: In the tumor context ("Macrophage: tumor_vs_others"), significant enrichment is observed for "Chemokine signaling pathway", "Cytokine-cytokine receptor interaction", "NF-kappa B signaling pathway", and "Leukocyte transendothelial migration". This profile suggests an active recruitment and polarization of macrophages, likely towards a tumor-associated macrophage (TAM) phenotype that often promotes tumor growth, angiogenesis, and immune suppression. GeneCards: NFKB1
• Endothelial Cells: "Endothelial cell: tumor_vs_others" shows enrichment in "HIF-1 signaling pathway", "PI3K-Akt signaling pathway", "Fluid shear stress and atherosclerosis", and "Focal adhesion". This indicates active angiogenesis (formation of new blood vessels) and vascular remodeling within the tumor, essential for providing nutrients and oxygen to the rapidly growing tumor.
• T cells (CD4+ and CD8+): Both "T cell CD4+: tumor_vs_others" and "T cell CD8+: tumor_vs_others" display enrichment in immune activation pathways such as "T cell receptor signaling pathway", "Chemokine signaling pathway", "Cytokine-cytokine receptor interaction", "NF-kappa B signaling pathway", and "Th1 and Th2 cell differentiation". The enrichment of "Apoptosis" in CD8+ T cells within the tumor context could suggest exhaustion or activation-induced cell death, limiting effective anti-tumor immunity. PubMed search: T cell exhaustion tumor microenvironment
• Smooth Muscle Cells: "Smooth muscle cell: tumor_vs_others" shows enriched "Focal adhesion" and "Regulation of actin cytoskeleton" pathways, which can be characteristic of stromal cells (like cancer-associated fibroblasts or pericytes derived from smooth muscle cells) involved in extracellular matrix remodeling and supporting tumor invasion and growth.

Clinical or Translational Implications

The GSEA results highlight several clinically relevant pathways in Kidney Cancer:

• Established Therapeutic Targets: The significant enrichment of HIF-1, PI3K-Akt, and mTOR signaling pathways in renal epithelial cells reinforces their role as key drivers of kidney cancer and validates existing therapeutic strategies targeting these pathways (e.g., VEGF inhibitors and mTOR inhibitors in renal cell carcinoma).
• Immunotherapy Context: The active immune signaling and differentiation pathways observed in macrophages and T cells within the tumor microenvironment suggest opportunities for immunotherapy, either by directly activating anti-tumor T cells or by reprogramming TAMs from a pro-tumorigenic to an anti-tumorigenic phenotype. The potential for T cell exhaustion (indicated by apoptosis) warrants strategies to overcome immune suppression.
• Angiogenesis: The activated angiogenic pathways in endothelial cells further confirm the importance of neo-angiogenesis in kidney cancer progression, supporting the rationale for anti-angiogenic agents.
• Metabolic Vulnerabilities: Upregulation of glycolysis in tumor cells points to metabolic vulnerabilities that could be exploited therapeutically, for instance, by targeting specific glycolytic enzymes.

20. Discussion

This single-cell analysis of kidney tissue unveils a comprehensive landscape of cellular and molecular alterations characteristic of Kidney Cancer. The malignant transformation of renal epithelial cells is profoundly marked by extensive aneuploidy and recurrent copy number variations, including amplifications of critical oncogenes such as SOX2, ECT2, MDM2, and CDK4. These genomic instabilities drive a pervasive reprogramming of tumor cell biology, evident in their dysregulated cell cycle with increased expression of proliferative genes like CCND1 and MYC, alongside activation of DNA damage response pathways such as CHEK1. The metabolic profile of these tumor cells dramatically shifts from oxidative phosphorylation to glycolysis, consistent with the Warburg effect, further supported by the upregulation of HIF-1, PI3K-Akt, and mTOR signaling, reflecting adaptation to the hypoxic tumor microenvironment and heightened biosynthetic demands. Concomitantly, tumor renal epithelial cells exhibit a striking loss of specialized kidney functions, indicative of dedifferentiation.

The tumor microenvironment (TME) is a highly active and remodelled ecosystem. While normal kidney tissue displays a stable cellular composition, tumor samples show a significant reduction in differentiated normal epithelial cells and an increased infiltration of immune and stromal cells. Macrophages represent a particularly prominent component of the TME. Although there is an overall dominance of M1-like macrophages, which typically mediate anti-tumor immunity, a statistically significant increase in the immunosuppressive M2C macrophage subpopulation in tumors indicates a complex and potentially dual role for tumor-associated macrophages (TAMs). These TAMs exhibit a distinct surfaceome, upregulating pro-tumorigenic markers such as CSF1R, TREM2, GPNMB, AXL, FOLR2, and the immune checkpoint SIGLEC10, suggesting their active participation in promoting tumor growth and immune evasion. T cells, including cytotoxic and regulatory subsets, are also present, with tumor-infiltrating CD4+ T cells showing signs of activation alongside markers (e.g., KLRB1) that may indicate functional dysregulation or exhaustion.

The intricate interplay within the TME is further illuminated by extensive cell-cell interaction (CCI) analyses. Tumor samples display a dramatically expanded and intensified interactome, predominantly involving aneuploid renal epithelial cells and macrophages, as well as smooth muscle cells. Key pro-tumorigenic axes, such as SPP1-integrin, CXCL12-CXCR4, and EGFR family (AREG, EREG, HBEGF, TGFA) signaling, are highly active, mediating macrophage recruitment, tumor cell invasion, and proliferation. Interactions involving LGALS3-MERTK contribute to immune evasion, while FN1-integrin and THBS1-CD36 crosstalk with smooth muscle cells drive extracellular matrix remodeling and angiogenesis. The prominent expression of surface markers on renal epithelial tumor cells, including established targets like EGFR, MET, CD47, and IL6R, and potential novel targets like CA12 and SLC2A1, underscores key oncogenic drivers, immune evasion strategies (e.g., MHC class II upregulation), and metabolic adaptations. The integration of genomic instability, metabolic reprogramming, and extensive, often immunosuppressive, cell-cell communication paints a detailed picture of Kidney Cancer pathogenesis, offering a rich framework for therapeutic intervention.

Hypotheses:

1. The extensive genomic instability and recurrent copy number variations, particularly amplifications of oncogenes like SOX2, ECT2, MDM2, and CDK4, are primary drivers of uncontrolled proliferation and dedifferentiation in aneuploid renal epithelial cells, underpinning kidney cancer pathogenesis.
2. The observed dominance of M1 macrophages co-existing with a significant increase in pro-tumorigenic M2C macrophages within the kidney tumor microenvironment creates a complex immune landscape where TAMs actively promote tumor progression and immune evasion through specific surface markers (e.g., CSF1R, AXL, SIGLEC10) and paracrine signaling.
3. Aberrant activation of EGFR signaling, driven by ligands such as AREG, EREG, and HBEGF from both malignant renal epithelial cells and surrounding TME components, forms a crucial autocrine and paracrine loop that sustains tumor cell proliferation, survival, and contributes to immune evasion.
4. The dysregulation of cell cycle genes, characterized by increased expression of proliferative drivers (e.g., CCND1, MYC) alongside activated checkpoint proteins (e.g., CHEK1, CDKN2A/B) in renal epithelial tumor cells, signifies a state of high replication stress that is ultimately overcome or subverted to fuel uncontrolled tumor growth.
5. The distinct surfaceome profiles and cell-cell interaction patterns involving tumor-infiltrating CD4+ T cells suggest an active yet potentially dysfunctional or exhausted state, where these cells are either ineffective in anti-tumor immunity or actively contribute to immunosuppression within the kidney tumor microenvironment.

Potential therapeutic targets:

1. EGFR (Epidermal Growth Factor Receptor): Overexpressed on malignant renal epithelial cells and involved in extensive cell-cell interactions within the tumor microenvironment, driving cell proliferation, survival, and angiogenesis through key signaling pathways like RAS/MAPK and PI3K/AKT/mTOR. Evidence: Upregulated in tumor renal epithelial cells (Section 14, Image 16). EGFR ligands (AREG, EREG, HBEGF, TGFA) and EGFR itself are involved in significant tumor-TME cell-cell interactions (Sections 12, 13, Image 14, Image 15). GSEA also shows PI3K-Akt signaling pathway enrichment (Section 19, Image 22). Validation: Evaluate the efficacy of existing EGFR inhibitors in kidney cancer cell lines and patient-derived organoids. Correlate EGFR expression and activation status with clinical response in patient cohorts treated with EGFR-targeted therapies. Agents: Erlotinib, Gefitinib, Cetuximab.
2. MET (MET Proto-Oncogene, Receptor Tyrosine Kinase): Overexpressed on malignant renal epithelial cells, promoting cell growth, survival, invasion, metastasis, and angiogenesis upon HGF binding. Evidence: Upregulated in tumor renal epithelial cells (Section 14, Image 16). Validation: Test MET inhibitors in kidney cancer models. Evaluate MET expression levels and activity as predictive biomarkers for response to MET-targeted therapies in clinical cohorts. Agents: Cabozantinib (approved for advanced renal cell carcinoma), Crizotinib.
3. CD47 (CD47 Molecule): Highly expressed on malignant renal epithelial cells, acting as a 'don't eat me' signal to evade phagocytosis by macrophages, thereby promoting immune escape. Evidence: Upregulated in tumor renal epithelial cells (Section 14, Image 16). Validation: Conduct in vitro phagocytosis assays with anti-CD47 blocking antibodies and kidney cancer cells. Assess the impact of CD47 blockade on tumor growth and immune infiltration in in vivo kidney cancer models. Agent: Magrolimab.
4. CSF1R (Colony Stimulating Factor 1 Receptor): Upregulated on tumor-associated macrophages (TAMs), critically involved in their recruitment, survival, proliferation, and pro-tumorigenic polarization within the TME, thus fostering immune suppression. Evidence: Highly expressed in tumor-associated macrophages (Section 15, Image 17). Macrophages show extensive involvement in tumor cell-cell interactions (Sections 11, 12, 13). Validation: Utilize CSF1R inhibitors in in vivo kidney cancer models to assess TAM depletion or reprogramming and its effect on tumor growth and immune responses. Monitor CSF1R expression in patient biopsies as a biomarker for response to anti-CSF1R therapies. Agents: Pexidartinib, Cabiralizumab.
5. AXL (AXL Receptor Tyrosine Kinase): Overexpressed on tumor-associated macrophages (TAMs) and potentially on tumor cells, promoting TAM-mediated immunosuppression, angiogenesis, and tumor cell survival/migration. Evidence: Highly expressed in tumor-associated macrophages (Section 15, Image 17). Validation: Test AXL inhibitors in kidney cancer cell lines and TAM co-culture models to determine effects on proliferation, migration, and immune modulation. Evaluate in vivo efficacy of AXL inhibitors alone or in combination with other agents. Agent: Bemcentinib.
6. SIGLEC10 (Sialic Acid Binding Ig Like Lectin 10): Upregulated on tumor-associated macrophages, functioning as an immune checkpoint by suppressing anti-tumor immune responses, particularly from T cells and NK cells, upon binding to sialylated ligands on tumor cells. Evidence: Highly expressed in tumor-associated macrophages (Section 15, Image 17). Validation: Develop and test SIGLEC10 blocking antibodies in in vitro macrophage-T cell co-culture assays to assess enhanced T cell activation and tumor killing. Evaluate in vivo anti-tumor efficacy of SIGLEC10 blockade in kidney cancer models. Agents: SIGLEC10 blocking antibodies (investigational).
7. CXCR4 (C-X-C Chemokine Receptor Type 4): The CXCL12-CXCR4 axis is highly active in the tumor microenvironment, driving tumor cell metastasis, recruitment of immunosuppressive cells (including TAMs), and angiogenesis. Evidence: CXCL12-CXCR4 interaction is significantly activated in tumor condition, involving renal epithelial tumor cells and macrophages (Section 12, Image 14). Validation: Investigate the effect of CXCR4 antagonists on tumor cell migration, invasion, and TAM recruitment in vitro and in vivo. Evaluate combination therapies with CXCR4 inhibitors to enhance anti-metastatic and immunotherapeutic effects. Agent: Plerixafor.
8. CDK4/6 (Cyclin-Dependent Kinase 4/6): Upregulation of CCND1 (Cyclin D1) in renal epithelial tumor cells drives uncontrolled progression through the G1 phase of the cell cycle, a hallmark of cancer. CDK4/6 are key kinases promoting this transition. Evidence: CCND1 shows significantly higher expressing cell fraction in tumor renal epithelial cells (Section 17, Image 19). Copy number variation analysis also mentions CDK4 amplification (Section 4, Image 5). Validation: Test CDK4/6 inhibitors on kidney cancer cell lines and patient-derived organoids to assess G1 cell cycle arrest and inhibition of proliferation. Correlate CCND1/CDK4 expression with sensitivity to CDK4/6 inhibitors in patient cohorts. Agents: Palbociclib, Ribociclib, Abemaciclib.
9. PD-1 / PD-L1 (Programmed Death-1 / Programmed Death-Ligand 1): The analysis reveals active immune signaling and T cell infiltration, along with potential T cell exhaustion (GSEA 'Apoptosis' in CD8+ T cells), indicating a dysregulated immune response that can be exploited by immune checkpoints like PD-1/PD-L1 to suppress anti-tumor immunity. Evidence: GSEA shows enrichment of T cell receptor signaling and apoptosis in T cells (Section 19, Image 22). CCI analysis in Section 13 included immune checkpoint pathway genes (e.g. CD274 for PD-L1) and showed active immune signaling like IFNG_Type_II_IFNR and CD86_CD28 interactions in the tumor TME, highlighting the importance of immune modulation. Validation: Confirm PD-L1 expression on tumor cells and immune cells in kidney cancer patient samples via immunohistochemistry. Evaluate the clinical efficacy of anti-PD-1/PD-L1 therapies, potentially in combination with other targeted agents to overcome resistance. Agents: Nivolumab, Pembrolizumab (anti-PD-1); Atezolizumab, Durvalumab, Avelumab (anti-PD-L1).

Follow-up validation ideas:

1. Validate recurrent CNVs (e.g., SOX2, ECT2, MDM2, CDK4 amplifications) in isolated renal epithelial tumor cells using FISH or array CGH on additional patient samples or kidney cancer cell lines.
2. Confirm the relative proportions of M1 and M2C macrophage subsets, along with the expression of key surface markers (e.g., CSF1R, AXL, SIGLEC10), in the tumor microenvironment using multi-parameter flow cytometry or multiplex immunofluorescence on fresh tumor biopsies.
3. Investigate the functional impact of identified cell-cell interactions (e.g., SPP1-integrin, CXCL12-CXCR4, EGFR family signaling, LGALS3-MERTK) on tumor cell proliferation, invasion, and immune cell modulation using in vitro co-culture systems with specific blocking antibodies or genetic perturbations.
4. Perform targeted RNA-seq or protein analysis (e.g., Western blot, IHC) to validate the differential expression of cell cycle genes (CCND1, MYC, CHEK1, CDKN2A/B) and metabolic markers (SLC2A1) in a larger cohort of kidney cancer patient samples.
5. Assess the functional state and anti-tumor activity of tumor-infiltrating CD4+ and CD8+ T cells through ex vivo cytokine production assays and proliferation studies, correlating findings with expression of activation/exhaustion markers (e.g., CD44, IL7R, KLRB1, MHC Class II).
6. Employ spatial transcriptomics or high-resolution imaging (e.g., Imaging Mass Cytometry) to map the precise localization and interaction partners of key cell types and their surface markers within the kidney tumor microenvironment.

Limitations:

The findings presented are based on computational analysis of single-cell RNA-seq data and represent inferred biological mechanisms rather than direct causal observations. The specific subtype and stage of Kidney Cancer cannot be definitively determined from this dataset, limiting the generalizability to all forms of kidney malignancy. While cell-cell interactions and marker expressions are identified, their functional significance and precise downstream effects require further experimental validation in vitro and in vivo. The current analysis does not fully resolve the spatial organization of cellular interactions within the kidney tissue. Furthermore, the variability observed between individual patient samples highlights tumor heterogeneity, implying that conclusions may not universally apply to every kidney cancer case and warrant validation in larger, independent cohorts.

21. Query List

1. Show and save UMAPs for condition, sample, celltype_major, celltype_minor, ploidy_dec, and celltype_subset in two columns.
2. Show celltype_major scores on UMAP and save the result.
3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
4. Select Renal Epithelial cells, show a CNV heatmap grouped by sample together with a summary of regions with significantly amplified copy numbers, and save the results.
5. Show and save UMAPs of CNV patterns colored by celltype_major, celltype_minor, ploidy_dec, condition, and sample in two columns.
6. Show and save a population bar plot of minor cell types.
7. Show and save a population bar plot of T cell subsets.
8. Show and save a population bar plot of macrophage subsets.
9. Show and save box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
10. Select Renal Epithelial cells, show their ploidy populations as a bar plot, and save the result.
11. Show and save cell-cell interaction patterns involving Renal Epithelial cells, Fibroblast, Macrophage, T cell, and other relevant cell types. Select at most 80 cell-cell interactions per group.
12. Find cell-cell interactions involving Renal Epithelial cells, major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents.
13. Find cell-cell interactions containing immune checkpoint and cell cycle pathway genes and involving Renal Epithelial cells, major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents.
14. Show marker expressions for Renal Epithelial cells in a dot plot, and save the result. Use only surfaceome markers, with at most 60 markers per condition. For the markers identified under each condition, distinguish between established therapeutic targets and less well-characterized markers with potential as therapeutic targets. For each marker, using the provided dataset context, describe the associated signaling pathways and mechanisms, relevant therapeutic agents, and supporting evidence.
15. Show marker expressions for Macrophage in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
16. Show marker expressions for T cell CD4+ in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
17. Among cell cycle pathway genes, select those with statistically significant expression differences between conditions in Renal Epithelial cells, show box plots, and save the result. Set max_n_items_to_plot to 24 and choose ncols based on the total number of panels for an overall width-to-height ratio of approximately 2:3.
18. Show and save Gene Ontology (GSA) analysis results for Renal Epithelial cells as a bar plot.
19. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.